<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN"  "JATS-archivearticle1-mathml3.dtd"><article xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" dtd-version="1.2"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn publication-format="electronic" pub-type="epub">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">79183</article-id><article-id pub-id-type="doi">10.7554/eLife.79183</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-275406"><name><surname>Jimenez-Sainz</surname><given-names>Judit</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1048-8623</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275407"><name><surname>Mathew</surname><given-names>Joshua</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-5743-2670</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275408"><name><surname>Moore</surname><given-names>Gemma</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-2656-0538</contrib-id><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275409"><name><surname>Lahiri</surname><given-names>Sudipta</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275410"><name><surname>Garbarino</surname><given-names>Jennifer</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-275411"><name><surname>Eder</surname><given-names>Joseph P</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-159983"><name><surname>Rothenberg</surname><given-names>Eli</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-1382-1380</contrib-id><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund5"/><xref ref-type="other" rid="fund6"/><xref ref-type="other" rid="fund7"/><xref ref-type="other" rid="fund8"/><xref ref-type="other" rid="fund9"/><xref ref-type="other" rid="fund10"/><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes" id="author-228203"><name><surname>Jensen</surname><given-names>Ryan B</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0002-9844-0789</contrib-id><email>ryan.jensen@yale.edu</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="other" rid="fund3"/><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf2"/></contrib><aff id="aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03v76x132</institution-id><institution>Department of Therapeutic Radiology, Yale University</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03j7sze86</institution-id><institution>Department of Medical Oncology, Yale University School of Medicine, Yale Cancer Center</institution></institution-wrap><addr-line><named-content content-type="city">New Haven</named-content></addr-line><country>United States</country></aff><aff id="aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ror">https://ror.org/0190ak572</institution-id><institution>Department of Biochemistry and Molecular Pharmacology, New York University</institution></institution-wrap><addr-line><named-content content-type="city">New York</named-content></addr-line><country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Aguilera</surname><given-names>Andrés</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yxnpp24</institution-id><institution>CABIMER, Universidad de Sevilla</institution></institution-wrap><country>Spain</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Ojala</surname><given-names>Paivi M</given-names></name><role>Senior Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/040af2s02</institution-id><institution>Translational Cancer Medicine Research Program, Faculty of Medicine, University of Helsinki</institution></institution-wrap><country>Finland</country></aff></contrib></contrib-group><pub-date publication-format="electronic" date-type="publication"><day>13</day><month>09</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>11</volume><elocation-id>e79183</elocation-id><history><date date-type="received" iso-8601-date="2022-04-01"><day>01</day><month>04</month><year>2022</year></date><date date-type="accepted" iso-8601-date="2022-09-12"><day>12</day><month>09</month><year>2022</year></date></history><pub-history><event><event-desc>This manuscript was published as a preprint at .</event-desc><date date-type="preprint" iso-8601-date="2021-09-25"><day>25</day><month>09</month><year>2021</year></date><self-uri content-type="preprint" xlink:href="https://doi.org/10.1101/2021.09.24.461749"/></event></pub-history><permissions><copyright-statement>© 2022, Jimenez-Sainz et al</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Jimenez-Sainz et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-79183-v3.pdf"/><self-uri content-type="figures-pdf" xlink:href="elife-79183-figures-v3.pdf"/><abstract><p>Pathogenic mutations in the BRCA2 tumor suppressor gene predispose to breast, ovarian, pancreatic, prostate, and other cancers. BRCA2 maintains genome stability through homology-directed repair (HDR) of DNA double-strand breaks (DSBs) and replication fork protection. Nonsense or frameshift mutations leading to truncation of the BRCA2 protein are typically considered pathogenic; however, missense mutations resulting in single amino acid substitutions can be challenging to functionally interpret. The majority of missense mutations in BRCA2 have been classified as Variants of Uncertain Significance (VUS) with unknown functional consequences. In this study, we identified three BRCA2 VUS located within the BRC repeat region to determine their impact on canonical HDR and fork protection functions. We provide evidence that S1221P and T1980I, which map to conserved residues in the BRC2 and BRC7 repeats, compromise the cellular response to chemotherapeutics and ionizing radiation, and display deficits in fork protection. We further demonstrate biochemically that S1221P and T1980I disrupt RAD51 binding and diminish the ability of BRCA2 to stabilize RAD51-ssDNA complexes. The third variant, T1346I, located within the spacer region between BRC2 and BRC3 repeats, is fully functional. We conclude that T1346I is a benign allele, whereas S1221P and T1980I are hypomorphic disrupting the ability of BRCA2 to fully engage and stabilize RAD51 nucleoprotein filaments. Our results underscore the importance of correctly classifying BRCA2 VUS as pathogenic variants can impact both future cancer risk and guide therapy selection during cancer treatment.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>dna repair</kwd><kwd>BRCA2</kwd><kwd>RAD51</kwd><kwd>homology-directed repair</kwd><kwd>variants</kwd><kwd>hereditary cancer</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000054</institution-id><institution>National Cancer Institute</institution></institution-wrap></funding-source><award-id>CA215990</award-id><principal-award-recipient><name><surname>Jensen</surname><given-names>Ryan B</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution>Women's Health Research at Yale</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jensen</surname><given-names>Ryan B</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution>The Gray Foundation</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jensen</surname><given-names>Ryan B</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution>Lion Heart Pilot Grant</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Jimenez-Sainz</surname><given-names>Judit</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>R35 GM134947</award-id><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><award-group id="fund6"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>AI153040</award-id><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><award-group id="fund7"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100000002</institution-id><institution>National Institutes of Health</institution></institution-wrap></funding-source><award-id>CA247773</award-id><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><award-group id="fund8"><funding-source><institution-wrap><institution>The V Foundation BRCA Research</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><award-group id="fund9"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/100004319</institution-id><institution>Pfizer</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><award-group id="fund10"><funding-source><institution-wrap><institution>Chavkin Philanthropic</institution></institution-wrap></funding-source><principal-award-recipient><name><surname>Rothenberg</surname><given-names>Eli</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>Novel variants in the BRC repeat region of BRCA2 were identified and comprehensively characterized as either deleterious or benign.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>BRCA2 (BReast CAncer type 2 susceptibility gene) is a mediator protein promoting homology-directed repair (HDR) of DNA double-strand breaks (DSBs) via RAD51-dependent DNA strand invasion, pairing, and exchange (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>; <xref ref-type="bibr" rid="bib61">Scully and Livingston, 2000</xref>; <xref ref-type="bibr" rid="bib69">Venkitaraman, 2002</xref>). BRCA2 binds and loads RAD51 onto single-stranded DNA (ssDNA) resulting from strand resection. Mechanistically, BRCA2 directs RAD51 onto ssDNA while limiting binding to double-stranded DNA (dsDNA), downregulates the ATPase activity of RAD51, and displaces Replication Protein A (RPA) from ssDNA (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>; <xref ref-type="bibr" rid="bib40">Liu et al., 2010</xref>; <xref ref-type="bibr" rid="bib68">Thorslund et al., 2007</xref>). Loss of BRCA2 in human cells leads to HDR defects, genomic instability, micronuclei formation, diminished fork protection following replication stress, impaired RAD51 foci formation in response to DNA damage, and sensitivity to chemotherapeutics such as platinum agents and PARP inhibitors (PARPi) (<xref ref-type="bibr" rid="bib1">Abul-Husn et al., 2019</xref>; <xref ref-type="bibr" rid="bib17">Chen et al., 1999</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 1998</xref>; <xref ref-type="bibr" rid="bib49">Moynahan et al., 2001</xref>; <xref ref-type="bibr" rid="bib52">Patel et al., 1998</xref>).</p><p>To date, four recognized domains in BRCA2 have emerged from both sequence based and structural studies (<xref ref-type="fig" rid="fig1">Figure 1A</xref>): an N-terminal region, eight BRC repeats located in the middle of the protein, an alpha helices region and three tandem oligonucleotide/oligosaccharide-binding folds (OB-folds) termed the DNA binding domain (DBD), and the C-terminal domain (CTD) (<xref ref-type="bibr" rid="bib6">Bignell et al., 1997</xref>; <xref ref-type="bibr" rid="bib46">McAllister et al., 1997</xref>; <xref ref-type="bibr" rid="bib73">Yang et al., 2002</xref>). The BRC repeats interact with RAD51 and distinct functions have been ascribed to each of two modules: BRC1-4 and BRC5-8 (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). The BRC1-4 module binds free monomeric RAD51 while BRC5-8 binds RAD51 only when assembled onto ssDNA (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). The DBD of BRCA2 has been shown to bind DSS1, ssDNA, and presumably dsDNA as well (<xref ref-type="bibr" rid="bib73">Yang et al., 2002</xref>). A nuclear export sequence (NES) in the DBD has been found to overlap with the binding region for DSS1 and a specific missense mutation (D2723H) that disrupts DSS1 binding results in BRCA2 export to the cytoplasm (<xref ref-type="bibr" rid="bib33">Jeyasekharan et al., 2013</xref>). The CTD (also known as TR2) binds RAD51 only when complexed with ssDNA as a nucleoprotein filament (similar to BRC5-8) and RAD51 filament binding is regulated by phosphorylation at the S3291 residue (<xref ref-type="bibr" rid="bib12">Carreira et al., 2009</xref>; <xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 1998</xref>; <xref ref-type="bibr" rid="bib21">Esashi et al., 2007</xref>; <xref ref-type="bibr" rid="bib47">Mizuta et al., 1997</xref>; <xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref>; <xref ref-type="bibr" rid="bib62">Sharan et al., 1997</xref>; <xref ref-type="bibr" rid="bib72">Wong et al., 1997</xref>). Putative nuclear localization signals (NLSs) are located in the CTD of BRCA2; however, surprisingly, it remains unclear how exactly nuclear/cytoplasmic trafficking of BRCA2 is regulated (<xref ref-type="bibr" rid="bib4">Bertwistle et al., 1997</xref>; <xref ref-type="bibr" rid="bib27">Han et al., 2008</xref>; <xref ref-type="bibr" rid="bib63">Spain et al., 1999</xref>; <xref ref-type="bibr" rid="bib74">Yano et al., 2000</xref>) (reviewed in <xref ref-type="bibr" rid="bib34">Jimenez-Sainz and Jensen, 2021</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>BRCA2 BRC residues S1221, T1346, and T1980 are conserved residues.</title><p>S1221P and T1980I are structurally predicted to disrupt BRC folding and RAD51 binding. (<bold>A</bold>) BRCA2 protein schematic depicting domain organization: 2XMBP tag, N-terminus, BRC repeats, DNA binding domain (DBD), and C-terminal domain (CTD). BRCA2 missense variants used in this study are indicated. (<bold>B</bold>) Multiple sequence alignment of BRCA2 amino acids flanking each missense variant from different organisms: S1221P (BRC2), T1346I (Spacer BRC2-3), and T1980I (BRC7). Residue corresponding to the missense variant is indicated in pink and conserved residues flanking the missense residue are indicated in light grey. Uniprot and ClustalX (70% threshold for shading) were used for the alignment. FxTASGK is a consensus motif important for RAD51 interactions depicted below BRC2 and BRC7. (<bold>C</bold>) Structural models based on 1N0W structure. Homology model comparison of BRC2 (orange) and BRC7 (yellow) based on the BRC4 (pink) structure. Top Inset: BRC2 (S1221), BRC4 (T1526), and BRC7 (T1980) overlayed to show conservation. Bottom Insets: predicted disruptions resulting from variants BRC2 (S1221P), BRC4 (T1526A), and BRC7 (T1980I). BRC4 T1526A is a previously characterized missense variant that disrupts RAD51 binding. RAD51 D187 residue is displayed in green. Clashes are indicated in red. Sequence alignment of BRC2, BRC4, and BRC7 repeats. Missense variant residues are boxed in red.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Contains BRCA2 sequence alignment depicting homology (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), SWISS-MODEL homology modeling reports (<xref ref-type="fig" rid="fig1">Figure 1C</xref>), close up views of BRC-RAD51 amino acid interactions (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig1-v3.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Polar contacts of S1221P, T1526A, and T1980I.</title><p>Homology model comparisons of BRC2 and BRC7 based on the BRC4 (1N0W) structure. Top Inset: Polar contacts (black dotted lines) within a BRC4 loop containing residue T1526. Bottom insets: Loss of polar contacts predicted by the S1221P variant within the BRC2 homology model (left), the T1526A variant within BRC4 (middle), and the T1980I variant within the BRC7 homology model (right). RAD51 D187 residue is displayed in green.</p><p><supplementary-material id="fig1s1sdata1"><label>Figure 1—figure supplement 1—source data 1.</label><caption><title>T1526 polar contacts.</title><p>T1526A polar contacts. T1526I polar contacts. T1526P polar contacts.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig1-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig1-figsupp1-v3.tif"/></fig></fig-group><p>The etiology of cancer-causing mutations in BRCA2 is complex with both germline and somatic mutations spanning the entire length of the protein. Nonsense mutations in BRCA2 leading to protein truncation generally predict pathogenicity, as deletion of the DBD would impair key HDR functions, and perhaps more importantly, deletion of NLSs at the C-terminus of BRCA2 result in mislocalization to the cytoplasm (<xref ref-type="bibr" rid="bib63">Spain et al., 1999</xref>). We and others have recently discovered that missense mutations in the DBD mislocalized BRCA2 to the cytosol leading to HR deficiency and sensitivity to crosslinking agents and PARPi (<xref ref-type="bibr" rid="bib33">Jeyasekharan et al., 2013</xref>; <xref ref-type="bibr" rid="bib34">Jimenez-Sainz and Jensen, 2021</xref>; <xref ref-type="bibr" rid="bib35">Jimenez-Sainz et al., 2022</xref>; <xref ref-type="bibr" rid="bib39">Lee et al., 2021</xref>). However, an estimated 80% of germline and somatic mutations identified in patients are missense, single amino acid substitutions in the full-length protein (data extracted from ClinVar and cBioPortal, accessed April 2021) (<xref ref-type="bibr" rid="bib34">Jimenez-Sainz and Jensen, 2021</xref>). Missense mutations often yield unknown impact on function and/or disease linkage and are referred to as Variants of Uncertain Significance (VUS). VUS are frequently found to be unique to individual families, and thus, in the absence of any functional insight, make clinical management of patients extremely challenging. In a recent search of ClinVar (accessed April 2021), more than 60% of the total identified BRCA2 mutations were VUS (<xref ref-type="bibr" rid="bib34">Jimenez-Sainz and Jensen, 2021</xref>). Notably, the majority of the 1388 missense mutations reported within the BRC repeats of BRCA2 are classified as VUS.</p><p>The significant role of the BRC repeats in binding, loading, and stabilizing RAD51 on ssDNA prompted us to study the functionality of variants in this domain. Moreover, the biochemical impact of missense mutations in a single BRC repeat, or between repeats, within the context of the full-length BRCA2 protein was unknown. We focused on two variants, S1221P and T1980I, situated within a conserved RAD51 binding core motif in BRC2 and BRC7 respectively. A third variant, T1346I, located in the spacer region between BRC2 and BRC3 was identified as a somatic tumor mutation in a patient undergoing treatment at the Yale Cancer Center (<xref ref-type="bibr" rid="bib41">Lo et al., 2003</xref>; <xref ref-type="bibr" rid="bib50">Olopade et al., 2003</xref>; <xref ref-type="bibr" rid="bib67">Tal et al., 2009</xref>). The variants were previously deposited in ClinVar lacking clinical interpretation and classified as VUS (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/51501/">https://www.ncbi.nlm.nih.gov/clinvar/variation/51501/</ext-link>,<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/455896/">https://www.ncbi.nlm.nih.gov/clinvar/variation/455896/</ext-link>, <ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/clinvar/variation/993173/">https://www.ncbi.nlm.nih.gov/clinvar/variation/993173/</ext-link>). Our findings reveal S1221P and T1980I substantially alter BRCA2 HDR protein activities that fail to be compensated for by the remaining seven BRC repeats. Altered functions include impaired cellular response to chemotherapeutics and reduced RAD51 foci following ionizing radiation induced DNA damage. We provide unique biochemical evidence that BRC2 S1221P and BRC7 T1980I fail to bind RAD51, disrupt the stabilization of RAD51-ssDNA complexes, and as a result, stimulation of RAD51-mediated DNA strand exchange activity is diminished. In contrast, the T1346I variant resembled the wild type BRCA2 in all respects and was presumably a benign passenger mutation.</p></sec><sec id="s2" sec-type="results"><title>Results</title><sec id="s2-1"><title>BRCA2 missense variants S1221P and T1980I predict disruption of BRC folding and RAD51 binding</title><p>Searching the ClinVar database, we identified two potentially pathogenic BRCA2 missense variants, S1221P and T1980I, located in BRC2 and BRC7, respectively (<xref ref-type="fig" rid="fig1">Figure 1A</xref>), and classified as VUS or ‘not yet reviewed’. S1221P and T1980I have been described as tumor-associated but detailed information regarding their biochemical functionality was unknown (<xref ref-type="bibr" rid="bib41">Lo et al., 2003</xref>; <xref ref-type="bibr" rid="bib67">Tal et al., 2009</xref>). In addition, we identified a BRCA2 T1346I variant as a somatic mutation from whole exome sequencing (WES) of a colorectal tumor specimen from the Yale Cancer Center. Interestingly, T1346I is located in the spacer region flanked by BRC2 and BRC3 and classified as a VUS. Sequence alignment across 9 different species reveal that the S1221 and T1980 residues are highly conserved (67% and 89% respectively) (<xref ref-type="fig" rid="fig1">Figure 1B</xref>), whereas T1346 is less well conserved (44%). Multiple studies have verified a conserved core motif within each BRC repeat, designated FxTASGK, that is crucial for RAD51 binding (<xref ref-type="bibr" rid="bib6">Bignell et al., 1997</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 1998</xref>; <xref ref-type="bibr" rid="bib41">Lo et al., 2003</xref>; <xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref>). Importantly, both the S1221 and T1980 residues are located directly within this motif (note boxed residues in <xref ref-type="fig" rid="fig1">Figure 1B</xref>). Given that structural information is only available for the BRC4 repeat crystallized with the core domain of RAD51 (<xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref>), we utilized the SWISS-MODEL server homology modelling pipeline which relies on ProMod3, an in-house comparative modelling engine based on OpenStructure (<xref ref-type="bibr" rid="bib5">Biasini et al., 2013</xref>; <xref ref-type="bibr" rid="bib64">Studer et al., 2021</xref>; <xref ref-type="bibr" rid="bib71">Waterhouse et al., 2018</xref>). We based our modeling on the BRC4 structure to determine if S1221P and T1980I would disrupt key contacts between the BRC2 and BRC7 repeats and RAD51 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>).</p><p>Residue T1526 in BRC4 (3<sup>rd</sup> amino acid position in FxTSAGK) is equivalent to S1221 and T1980 in BRC2 and BRC7, respectively (<xref ref-type="fig" rid="fig1">Figure 1C</xref><bold>, lower sequence alignment</bold>). T1526 is buried in a hydrophobic pocket formed by RAD51 (<xref ref-type="fig" rid="fig1">Figure 1C</xref><bold>, center panel</bold>) (<xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref>) and the missense mutation, T1526A, diminishes BRC4 functions (<xref ref-type="bibr" rid="bib12">Carreira et al., 2009</xref>). Modeling of the T1526A substitution does not lead to steric clashing, however, could disassemble the BRC4 loop conformation (hydrophobic contacts F1524, A1527 and K1530 and polar contacts T1526 and S1528) necessary for RAD51 binding (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1</xref>; <xref ref-type="bibr" rid="bib12">Carreira et al., 2009</xref>). Mutating S1221 to proline in BRC2 (S1221P) predicts increased steric hindrance resulting in a loop to improperly fold to accommodate the bulkier sidechain (<xref ref-type="fig" rid="fig1">Figure 1C</xref><bold>, left panel</bold>). Changing T1980 in BRC7 to isoleucine (T1980I) requires a larger sidechain to be incorporated into the structure but with more flexibility than proline. If T1980I is oriented to not misfold, the sidechain is predicted to block RAD51 binding as it would clash with RAD51 residue D187 (<xref ref-type="fig" rid="fig1">Figure 1C</xref><bold>, right panel</bold>). Additionally, S1221P and T1980I substitutions would predict loss of multiple polar contacts (Figure S1) potentially disrupting the BRC structure and RAD51 interactions. Overall, the structural modeling of S1221P and T1980I predicts that either misfolding or steric clashes between residues within the BRC-RAD51 interface will obstruct interactions. As no structural information exists for the spacer region between BRC2 and BRC3 to date, we were unable to model the T1346I mutation.</p></sec><sec id="s2-2"><title>S1221P and T1980I variants are defective in response to chemotherapeutics and ionizing radiation</title><p>The sequence conservation and homology modeling analysis suggested S1221P and T1980I disrupt RAD51 interactions, therefore, we directly tested whether the variants were capable of functionally complementing BRCA2-deficient cells. Full-length BRCA2 cDNA constructs were fused to a tandem repeat of the maltose binding protein tag (2XMBP) which stabilizes and increases BRCA2 expression as previously described (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>). We stably expressed the variants in DLD1 BRCA2<sup>-/-</sup> cells (<xref ref-type="bibr" rid="bib29">Hucl et al., 2008</xref>) and successfully derived single-cell clones expressing S1221P, T1346I, and T1980I (<xref ref-type="fig" rid="fig2">Figure 2A</xref>, <xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1A</xref>). All variants localized to the nucleus (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref><bold>, left panel</bold>) as expected. Interestingly, as first described by Baker (<xref ref-type="bibr" rid="bib42">Magwood et al., 2013</xref>) and confirmed in a subsequent paper from our group (<xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>), re-introduction of recombinant BRCA2 protein in deficient cells increases total expression levels of RAD51 (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). The basal localization pattern of RAD51 also changed from a diffuse cytoplasmic/nuclear staining in null cells to a bright distinct signal in the nucleus upon re-expression of wild type (WT) BRCA2 and the variants (<xref ref-type="fig" rid="fig2s1">Figure 2—figure supplement 1B</xref>, <bold>middle panel</bold>).</p><fig-group><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>S1221P and T1980I only partially complement BRCA2 knockout cells in response to DNA damage.</title><p>T1346I fully rescues DNA damage sensitivity and RAD51 foci formation upon irradiation. (<bold>A</bold>) Western blot of total cellular lysates from DLD-1 BRCA2<sup>-/-</sup> cells stably transfected with either empty vector (BRCA2<sup>-/-</sup>) or BRCA2 Wild Type (WT), BRCA2 S1221P (BRC2), T1346I (Spacer BRC2-3), and T1980I (BRC7) full-length BRCA2 cDNA constructs. BRCA2 was detected with an MBP antibody. 2XMBP-BRCA2 (470 kDa), and RAD51 (37 kDa). (<bold>B</bold>) Clonogenic survival analyses of stable cell lines treated with mitomycin C (MMC), cisplatin, Olaparib, and Talazoparib. Error bars represent the S.D. for two biological independent experiments. (<bold>C</bold>) Immunofluorescence images and quantification of RAD51 (green) and gammaH2AX (red) foci, and DAPI staining to visualize nuclei (blue, grey) and micronuclei (grey). Representative images at 6 hr post-IR (12 Gy). Quantification of four biological independent experiments and statistical analysis t-test and one-way ANOVA. Scale bar represents 50 µm. p-value &lt;0.05 p-value &lt;0.0001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Contains original gel images depicting cropped regions used for <xref ref-type="fig" rid="fig2">Figure 2A</xref>, clonogenic survival data for <xref ref-type="fig" rid="fig2">Figure 2B</xref>, foci data for <xref ref-type="fig" rid="fig2">Figure 2C</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig2-v3.tif"/></fig><fig id="fig2s1" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 1.</label><caption><title>Expression and nuclear localization of S1221P, T1346I, and T1980I BRCA2 proteins.</title><p>(<bold>A</bold>) Western blot of total cellular lysates from DLD1 and DLD-1 BRCA2<sup>-/-</sup> cells stably transfected with either empty vector (BRCA2<sup>-/-</sup>) or BRCA2 Wild Type (WT), BRCA2 S1221P (BRC2), T1346I (Spacer BRC2-3), and T1980I (BRC7) full-length BRCA2 cDNA constructs. BRCA2 was detected with rabbit anti-BRCA2 antibody. 2XMBP-BRCA2 (470 kDa), and RAD51 (37 kDa). (<bold>B</bold>) Localization by immunofluorescence in untreated BRCA2<bold><sup>-/-</sup></bold> cells stably expressing WT, S1221P, T1346I, and T1980I BRCA2 proteins. Representative images of 2XMBP-BRCA2 (red, anti-MBP), RAD51 (green), and nuclei (blue).</p><p><supplementary-material id="fig2s1sdata1"><label>Figure 2—figure supplement 1—source data 1.</label><caption><title>Raw Nt Ct BRCA2 RAD51.</title><p>Raw Stain Free. Nt Ct BRCA2 RAD51 highlighedbandsandlabels.</p></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig2-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig2-figsupp1-v3.tif"/></fig><fig id="fig2s2" position="float" specific-use="child-fig"><label>Figure 2—figure supplement 2.</label><caption><title>BRCA2<sup>-/-</sup> cells stably expressing full-length BRCA2 S1221P and T1980I proteins only partially rescue sensitivity to crosslinking agents (MMC or cisplatin) and PARP inhibitors (Olaparib or Talazoparib).</title><p>The T1346I protein rescues to the same extent as WT. (<bold>A</bold>) Representative images of cell colonies stained with crystal violet 14 days after treatment. PE; plating efficiency. Treatments: 2.5 µM MMC 1 hr, 25 µM Cisplatin 1 hr, 15 µM Olaparib 24 hr, 20 nM Talazoparib 24 hr. (<bold>B</bold>) Plating efficiency of BRCA2<sup>-/-</sup> cells stably expressing BRCA2.</p><p><supplementary-material id="fig2s2sdata1"><label>Figure 2—figure supplement 2—source data 1.</label><caption><title>Revised plating efficiency.xlsx.</title></caption><media mimetype="application" mime-subtype="xlsx" xlink:href="elife-79183-fig2-figsupp2-data1-v3.xlsx"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig2-figsupp2-v3.tif"/></fig></fig-group><p>Strikingly, in BRCA2 null cells, neither expression of the S1221P nor the T1980I variant was able to rescue survival to the same level as WT BRCA2 in response to crosslinking agents mitomycin C (MMC) and cisplatin (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). Notably, the two variants did not track with the empty vector control cells (BRCA2<sup>-/-</sup>) suggesting partial complementation. The response of S1221P and T1980I to PARPi (olaparib and talazoparib) was modestly more robust than to crosslinkers but did not rescue to the same extent as WT BRCA2. T1346I provided a full rescue in response to all chemotherapeutic agents tested suggesting T1346I is a benign variant (<xref ref-type="fig" rid="fig2">Figure 2B</xref>). The differential responses of S1221P and T1980I could not be explained by a difference in plating efficiencies (<xref ref-type="fig" rid="fig2s2">Figure 2—figure supplement 2</xref>). Overall, the results imply that S1221P and T1980I are hypomorphic alleles of BRCA2.</p><p>RAD51 foci formation in the nuclei of ionizing radiation damaged cells has long been an established biomarker to indicate protein recruitment and functional engagement of homologous recombination at sites of DNA DSBs (<xref ref-type="bibr" rid="bib25">Haaf et al., 1995</xref>; <xref ref-type="bibr" rid="bib57">Rothkamm et al., 2015</xref>). We examined RAD51 foci at 6 hr (peak foci) following treatment with 12 Gy of ionizing radiation (<xref ref-type="fig" rid="fig2">Figure 2C</xref>). Phosphorylation of gammaH2AX was used as a surrogate marker for DNA DSBs to ensure damage inflicted was comparable amongst all cell lines (<xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). WT BRCA2 and T1346I restored RAD51 foci in DLD1 BRCA2 deficient cells whereas S1221P and T1980I exhibited a significantly lower percentage of cells with foci indicating a partial defect in HDR. Micronuclei formation is an indicator of genomic instability and BRCA2 deficient cells, including DLD1 BRCA2 knockout cells, show elevated levels of micronuclei (<xref ref-type="bibr" rid="bib3">Ban et al., 2001</xref>; <xref ref-type="bibr" rid="bib28">Heddle et al., 1983</xref>). While WT BRCA2 and T1346I were able to suppress micronuclei formation, T1980I was unable to do so, and S1221P appeared to exacerbate micronuclei formation (see <xref ref-type="fig" rid="fig2">Figure 2C</xref> <bold>DAPI panels (right) &amp; quantitation in lower graph</bold>).</p></sec><sec id="s2-3"><title>S1221P and T1980I, but not T1346I, are defective in HDR and fork protection</title><p>We used a CRISPR-Cas9 based gene-targeting assay to investigate whether S1221P, T1980I, and T1346I affect HDR (<xref ref-type="fig" rid="fig3">Figure 3A</xref>; <xref ref-type="bibr" rid="bib51">Orthwein et al., 2015</xref>; <xref ref-type="bibr" rid="bib54">Pinder et al., 2015</xref>; <xref ref-type="bibr" rid="bib77">Zhao et al., 2017</xref>). As expected, WT BRCA2 complementation increased the percentage of correctly targeted Clover positive cells at the LMNA locus compared to DLD1 BRCA2<sup>-/-</sup> cells (<xref ref-type="fig" rid="fig3">Figure 3B and C</xref>). In contrast, expression of S1221P or T1980I was unable to rescue HDR-mediated gene targeting to the same extent as WT BRCA2 detected as a lower percentage of Clover positive cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>). In addition to the canonical HDR functions of loading and stimulating RAD51 nucleation onto resected DNA, BRCA2 has been shown to protect stalled replication forks from nucleolytic degradation by nucleases such as MRE11 (<xref ref-type="bibr" rid="bib59">Schlacher et al., 2011</xref>). Fork protection functionality was investigated using a sequential dual label approach. Cells were labeled with thymidine analogues, CldU and IdU, for 30 min followed by a five hour hydroxyurea (HU) treatment (<xref ref-type="fig" rid="fig3">Figure 3D</xref>; <xref ref-type="bibr" rid="bib45">Maya-Mendoza et al., 2013</xref>; <xref ref-type="bibr" rid="bib59">Schlacher et al., 2011</xref>). Representative images of individual fibers as well as a dot plot analysis of the IdU/CldU ratio are shown in <xref ref-type="fig" rid="fig3">Figure 3E and F</xref>, respectively. Our results (<xref ref-type="fig" rid="fig3">Figure 3F</xref>) confirm previous studies (<xref ref-type="bibr" rid="bib59">Schlacher et al., 2011</xref>) in that DLD1 BRCA2<sup>-/-</sup> cells have a defect in HU-induced fork protection compared to BRCA2 WT complemented cells (24% reduction). T1346I protected forks similar to WT BRCA2, however, both S1221P and T1980I exhibited deficits (11–24% reduction).</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>S1221P and T1980I exhibit defects in HDR and fork protection.</title><p>(<bold>A</bold>) Schematic of the Clover-LMNA HDR assay. (<bold>B</bold>) Immunofluorescence images and quantification of Clover-LMNA HDR (green) and DAPI staining to visualize nuclei (blue) 96 hours post-transfection (threshold 0.25). (<bold>C</bold>) Quantification of the percentage of cells Clover positive in 4 independent experiments. (<bold>D</bold>) Schematic of CldU/IdU pulse-labeling followed by a 5 hr hydroxyurea (HU; 4 mM) treatment with representative images (<bold>E</bold>) of CldU (Red) and IdU (Green) replication tracts after HU treatment. (<bold>F</bold>) Dot plot of IdU to CldU tract length ratios for individual replication forks in HU-treated cells. All samples are normalized to BRCA2 WT (ratio = 1, i.e., functional fork protection). The median value of 100 or more IdU and CldU tracts per experimental condition is indicated. p-value &lt;0.05, p-value &lt;0.01, p-value &lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Contains quantification of clover positive cells (<xref ref-type="fig" rid="fig3">Figure 3C</xref>), images of DNA fibers (<xref ref-type="fig" rid="fig3">Figure 3E</xref>), DNA fiber analysis (<xref ref-type="fig" rid="fig3">Figure 3F</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig3-v3.tif"/></fig></sec><sec id="s2-4"><title>Individual S1221P and T1980I BRC mutations eliminate binding to RAD51</title><p>To interrogate protein interactions, we took advantage of our 2XMBP tagged full-length BRCA2 constructs stably expressed in DLD1 BRCA2<sup>-/-</sup> cells and performed amylose pull-downs to capture BRCA2 and probe for endogenous RAD51 binding (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1A</xref>). Equal levels of RAD51 were pulled down by WT BRCA2 and each variant despite the presence of individual BRC mutations. We performed the same experiment in a transient transfection approach in 293T cells and observed comparable levels of RAD51 binding across all proteins (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1B</xref>).</p><p>We reasoned that full-length BRCA2 S1221P and T1980I variants appear to bind RAD51 in an equivalent manner to the WT protein either due to the insensitivity of our assay conditions or to the presence of the remaining seven wild type BRC repeats masking the defect in a single BRC repeat. We queried a panel of 2XMBP-BRC repeats consisting of individual as well as multiple BRC repeat fragments expressed in 293T cells: BRC1, 2, 4, 7, BRC1-2, BRC3-4, BRC5-6, BRC7-8, BRC1-4, BRC5-8, and BRC1-8, analyzed as above to assess RAD51 binding characteristics (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A, B</xref>). To our surprise, BRC7-8 bound RAD51 while BRC5-6 and the BRC5-8 region did not. In a previous study, we found that a BRC5-8-DBD fusion protein also failed to bind RAD51 (<xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). Conversely, BRC4, BRC1-4, and BRC1-8 fusions with the DBD displayed robust RAD51 binding (<xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). Prior yeast two-hybrid analyses established that all BRC repeats interact with RAD51 except for BRC5 and BRC6 in agreement with a separate study demonstrating that GFP-RAD51 binds GST-BRC7-8 (<xref ref-type="bibr" rid="bib72">Wong et al., 1997</xref>; <xref ref-type="bibr" rid="bib75">Yu et al., 2003</xref>). Indeed, we confirmed that BRC7 alone can bind RAD51 under our pull-down conditions (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, lane 11 and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, lane 15), albeit to a much lesser extent than BRC2 (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, lane 9).</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>BRC2-S1221P and BRC7-T1980I abolish RAD51 binding.</title><p>(<bold>A</bold>) Schematic of amylose pull-down reaction to detect RAD51 binding. (<bold>B</bold>) Total cellular lysates (TCL) and amylose pull-downs from HEK 293T cells transiently transfected with 2XMBP, 2XMBP-BRC2, 2XMBP-BRC2 S1221P, 2XMBP-BRC7, and 2XMBP-BRC7 T1980I. Western blot: anti-MBP was used to detect 2XMBP-BRC and anti-RAD51 to detect endogenous RAD51. (<bold>C</bold>) Schematic of aminolink-conjugated resin reaction to BRC peptides and pull-down reaction to detect purified RAD51 binding. (<bold>D</bold>) Synthesized peptides BRC2, BRC2 S1221P, BRC7, BRC7 T1980I (35 amino acids) were conjugated to aminolink resin and incubated with purified RAD51. Western blot using RAD51 antibody to detect unbound and bound RAD51 after washes and elution of proteins in laemmli sample buffer. (<bold>E</bold>) Amylose pull-downs in HEK 293T cells transiently transfected with 2XMBP, 2XMBP-BRC2, 2XMBP-BRC2-S1221P, 2XMBP-BRC7, 2XMBP-BRC7 T1980I, wild type HA-RAD51, and T131P HA-RAD51. Anti-MBP was used to detect 2XMBP-BRC proteins. HA antibody was used to detect recombinant RAD51.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Contains original (uncropped) gel images for <xref ref-type="fig" rid="fig4">Figure 4B, D, E</xref>.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig4-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig4-v3.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>S1221P, T1346I, and T1980I full-length BRCA2 proteins bind RAD51.</title><p>(<bold>A</bold>) Western blots of total cellular lysates (TCL) (left gel) or amylose pull-downs (right gel) from BRCA2<sup>-/-</sup> cells stably expressing full-length BRCA2 WT, S1221P, T1346I, and T1980I. 2XMBP-BRCA2 (470 kDa) detected using a C-terminal antibody. Depicted RAD51 is the endogenous protein (37 kDa). (<bold>B</bold>) Western blots of total cellular lysates (TCL) and amylose pull-downs from HEK 293T cells transiently transfected with 2XMBP-BRCA2 WT, S1221P, T1346I, and T1980I full-length constructs. Anti-MBP antibody was used for BRCA2 detection. Depicted RAD51 is the endogenous protein. Lower red arrow in the Stain Free panel indicates 2XMBP (84 kDa) and upper red arrow indicates 2XMBP-BRCA2 (470 kDa) expression. Graphs on the right represent relative RAD51 expression levels using densitometric analysis from the western blots of total cellular lysates. Quantification of four biological independent experiments and statistical analysis t-test of each sample compared to BRCA<sup>-/-</sup>. p-value &lt; 0.05.</p><p><supplementary-material id="fig4s1sdata1"><label>Figure 4—figure supplement 1—source data 1.</label><caption><title>Contains band quantification and original (uncropped) gel images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig4-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig4-figsupp1-v3.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>BRC1-2, BRC7-8, BRC2, and BRC7 bind RAD51 whereas BRC2-S1221P and BRC7-T1980I ablate RAD51 binding.</title><p>(<bold>A</bold>) Western blots of total cellular lysates (TCL) and amylose pull-downs from HEK 293T cells transiently transfected with 2XMBP or 2XMBP-BRC repeat constructs: BRC1-8, BRC1-4, BRC5-8, BRC1-2, BRC3-4, BRC 5–6, and BRC 7–8. (<bold>B</bold>) Western blots of total cellular lysates (TCL) and amylose pull-downs from HEK 293T cells transiently transfected with 2XMBP or 2XMBP-BRC repeat constructs: BRC1, BRC2, BRC4, BRC7, BRC2-S1221P, BRC4-T1526A, and BRC7-T1980I. BRC proteins were detected with an MBP antibody (<bold>C</bold>) Pull-downs with synthetic peptides: BRC2, BRC2-S1221P, BRC7, BRC7-T1980I fused to aminolink resin. Ten µL of aminolink resin conjugated to each peptide was incubated with increasing concentrations of purified RAD51 protein. Western blots (anti-RAD51) from unbound (UB) and bound (<bold>B</bold>) elutions from aminolink resin. (<bold>D</bold>) RAD51 self-interaction pull-down assay. Western blots of total cellular lysates and amylose pulldowns from HEK 293T cells transiently co-transfected with 2XMBP or 2XMBP-RAD51 and HA-RAD51 or HA-RAD51 T131P. RAD51 was detected with an HA antibody. (<bold>E</bold>) Western blots from peptide competition assay. Purified RAD51 previously incubated with or without BRC2 or BRC2-S1221P peptide was utilized in an amylose pull-down assay with 2XMBP-BRC4 or 2XMBP-BRC4-T1526A recombinantly expressed in HEK 293T cells. BRC repeat proteins detected with anti-MBP. Purified RAD51 eluted from amylose beads bound to 2XMBP-BRC peptide detected with anti-RAD51.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Contains original (uncropped) gel images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig4-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig4-figsupp2-v3.tif"/></fig></fig-group><p>To circumvent the potential for compensatory BRC repeat interactions with RAD51, we generated a single BRC2 construct incorporating the S1221P variant, and likewise, created a BRC7 construct with the T1980I variant. We included BRC4 T1526A in our analysis, as this variant has been described to interfere with RAD51 binding (<xref ref-type="bibr" rid="bib67">Tal et al., 2009</xref>). The 2XMBP tag alone was used as a negative control in all experiments. By focusing on the individual BRC repeats, we found that both S1221P and T1980I demonstrated no detectable RAD51 interaction in our pull-down analyses in 293T cells (<xref ref-type="fig" rid="fig4">Figure 4B</xref>, compare lanes 9 &amp; 10 and lanes 11 &amp; 12 and <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, lanes 16 &amp; 18). As expected, T1526A disrupts the RAD51 interaction although we observed some residual binding (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2B</xref>, lane 17). To further confirm our results in an orthogonal approach, we synthesized the individual peptides (33 amino acids), conjugated them to aminolink resin, and incubated the BRC peptides with purified RAD51. The results clearly show that wild type BRC2 and BRC7 peptides interact with RAD51 (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, lanes 7 &amp; 9) while the S1221P and T1980I peptides abolish binding (<xref ref-type="fig" rid="fig4">Figure 4D</xref>, lanes 8 &amp; 10). Pre-incubation of wild type BRC2 peptide, but not the S1221P variant, with purified RAD51 protein prevents binding to BRC4 confirming the stable association of BRC2 with RAD51 and lack of binding by the S1221P variant (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2E</xref>, compare lane 8 and 9).</p><p>The BRC repeats are composed of two modules: BRC1-4 mediates binding to free monomeric RAD51 while BRC5-8 binds and stabilizes RAD51-ssDNA complexes (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>). To reconcile our pull-down data showing that BRC7 interacts with RAD51 in the absence of pre-assembled filaments on ssDNA, we considered that RAD51, both in purified form and likely in cell extracts, may self-oligomerize resembling a filament that mediates binding to both BRC7 and the BRC7-8 peptides (<xref ref-type="bibr" rid="bib65">Subramanyam et al., 2018</xref>). We addressed this discrepancy by interrogating whether the RAD51 T131P mutant was capable of BRC7 interaction. T131P is located in the Walker A domain of RAD51, alters ATP binding and hydrolysis behavior preventing filament formation, and acts as a dominant negative in the presence of WT RAD51 (<xref ref-type="bibr" rid="bib58">San Filippo et al., 2006</xref>; <xref ref-type="bibr" rid="bib70">Wang et al., 2015</xref>; <xref ref-type="bibr" rid="bib76">Zadorozhny et al., 2017</xref>). We confirmed that T131P does not self-associate (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2D</xref>, lane 8). Indeed, co-incubation of RAD51 T131P with BRC2 exhibited similar binding as wild type RAD51 (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, compare lanes 2 &amp; 7), whereas binding of T131P to BRC7 was greatly reduced (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, lane 8). These results reaffirm that BRC2 binds the monomeric form of RAD51 while BRC7 presumably binds oligomers or self-polymerized forms of RAD51. As expected, the S1221P and T1980I variants failed to bind both wild type RAD51 and the T131P mutant (<xref ref-type="fig" rid="fig4">Figure 4E</xref>, lanes 4–5 and lanes 9–10).</p></sec><sec id="s2-5"><title>S1221P and T1980I fail to stimulate RAD51-ssDNA complex formation</title><p>To determine whether the lack of RAD51 binding by BRC2-S1221P and BRC7-T1980I alters stimulation/stabilization of a RAD51-ssDNA complex, we utilized an electrophoretic mobility-shift assay (EMSA) under conditions previously described (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>). First, we purified BRC2, BRC7, BRC2-S1221P and BRC7-T1980I from HEK293T cells (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1A</xref>). We titrated RAD51 protein to determine that 10 nM of RAD51 is the optimal concentration at which RAD51-ssDNA complex formation is approximately 20–30% (<xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1B</xref>). Then, RAD51 was incubated with purified BRC2, BRC2-S1221P, BRC7, and BRC7-T1980I proteins followed by the addition of ssDNA (dT40) (<xref ref-type="fig" rid="fig5">Figure 5A</xref>). As anticipated, increasing concentrations of BRC2 and BRC7 stimulated binding of RAD51 to ssDNA (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, lanes 3–6, left panel and lanes 3–6, right panel). In contrast, BRC2-S1221P (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, lanes 7–10, left panel) and BRC7-T1980I (<xref ref-type="fig" rid="fig5">Figure 5B</xref>, lanes 7–10, right panel) did not stimulate RAD51-ssDNA complex formation even at the highest concentration of BRC proteins (2 µM) tested (see quantitation in <xref ref-type="fig" rid="fig5">Figure 5C</xref>).</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>BRC2-S1221P and BRC7-T1980I fail to stimulate RAD51-ssDNA complex formation.</title><p>(<bold>A</bold>) Schematic of reaction to assay BRC repeat stimulation of RAD51-ssDNA complex formation by EMSA. RAD51 was pre-incubated with increasing amounts of BRC protein for 15 min then radiolabeled ssDNA (dT40) was added for 40 min. All reactions were incubated at 37 degrees and visualized on a 6% TAE polyacrylamide gel. (<bold>B</bold>) Autoradiograms of EMSA gels depicting increasing concentration of BRC proteins: BRC2, BRC2-S1221P, BRC7, BRC7-T1980I incubated with 10 nM RAD51 and 400 pM ssDNA (dT40*). Lane 1 is no protein control. Lane 2 is RAD51 alone. (<bold>C</bold>) Quantification of BRC-RAD51-ssDNA complexes calculated from gels shown in B. Error bars represent the S.D. for two biological independent experiments. (<bold>D</bold>) Schematic of biotinylated DNA pull-down assay. Purified BRC proteins were pre-incubated with increasing concentrations of purified RAD51 for 10 min. Biotinylated ssDNA (167-mer) was then added for 10 min to allow nucleoprotein filament formation and captured on magnetic streptavidin beads. The beads were then washed, eluted in sample buffer, analyzed by SDS-PAGE, and bound RAD51 was detected by western blotting using an anti-RAD51 antibody. (<bold>E</bold>) Western blot depicting RAD51 pulled down and eluted from biotin-DNA-BRC-RAD51 complexes. 0, 50, or 100 nM RAD51 was pre-incubated with 80 nM of BRC peptide, incubated with biotin-ssDNA, washed extensively, and eluted. Densitometric quantitation of RAD51 binding at 100 nM is indicated in the boxes below. (<bold>F</bold>) Schematic depicting single-molecule FRET (smFRET) assay with 30-nucleotide 3’-tail ssDNA. Addition of BRC7<sub>WT</sub> results in an increase in RAD51 binding leading to a transition from high FRET (DNA-only) to medium FRET (BRC7<sub>WT</sub> and RAD51-bound). Histograms display a shift (ΔE<sub>FRET</sub> = 11%) upon addition of 20 nM BRC7<sub>WT</sub> and 20 nM RAD51 that is not observed in BRC7<sub>T1980I</sub> or in the BRC2 peptides (WT and S1221P). Representative histograms do not include zero FRET values or photobleached portions of the FRET trajectories. A minimum of 250 smFRET trajectories were utilized to generate each histogram.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Contains uncropped gel images (<xref ref-type="fig" rid="fig5">Figure 5B</xref>), EMSA band quantification (<xref ref-type="fig" rid="fig5">Figure 5C</xref>), biotin-DNA pulldown band quantification (<xref ref-type="fig" rid="fig5">Figure 5E</xref>), histogram data (<xref ref-type="fig" rid="fig5">Figure 5F</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig5-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig5-v3.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Purified proteins used for biochemical studies.</title><p>Optimization of RAD51-ssDNA EMSA. (<bold>A</bold>) Coomassie stained gel of 2XMBP-BRC fragments BRC2, BRC2-S1221P, BRC7, and BRC7-T1980I proteins purified from HEK 293T cells. Human RAD51 and RPA proteins purified from bacteria. (<bold>B</bold>) Increasing concentrations of purified RAD51 were incubated with radiolabeled dT40 and analyzed by EMSA.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Contains original (uncropped) gel images.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig5-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig5-figsupp1-v3.tif"/></fig><fig id="fig5s2" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 2.</label><caption><title>smFRET control assays highlighting BRC wildtype and mutant proteins (S1221P and T1980I) show no change in FRET efficiency in the absence of RAD51.</title><p>(<bold>A</bold>) Histograms depicting: DNA only, BRC storage buffer only, individual BRC repeat proteins in the absence of RAD51 protein, and 400 nM RAD51 alone. Representative histograms do not include zero FRET values or photobleached portions of the FRET trajectories. (<bold>B</bold>) Illustration of smFRET assay consisting of a 3’-tail DNA (30 nucleotide ssDNA overhang) tethered to a dsDNA substrate attached to the surface. (<bold>C</bold>) Representative smFRET trajectories for DNA only, BRC storage buffer, BRC peptides (wildtype and mutants), and RAD51 alone. At 400 nM RAD51, there is a notable decrease in acceptor intensity (red) indicating RAD51 binding and transition from a high FRET state (DNA-only) to a low FRET state (RAD51-bound). The donor traces are in green, acceptor in red, and FRET trajectories are shown in black.</p><p><supplementary-material id="fig5s2sdata1"><label>Figure 5—figure supplement 2—source data 1.</label><caption><title>Contains data and traces for single molecule FRET.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig5-figsupp2-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig5-figsupp2-v3.tif"/></fig><fig id="fig5s3" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 3.</label><caption><title>Representative trajectories corresponding to histograms in <xref ref-type="fig" rid="fig5">Figure 5F</xref>.</title><p>Representative individual smFRET trajectories for DNA only, 20 nM RAD51, 20 nM RAD51 in presence of 20 nM BRC2 (WT or S1221P), and 20 nM RAD51 in presence of 20 nM BRC7 (WT or T1980I). The donor traces are in green, acceptor in red, and FRET trajectories are shown in black.</p><p><supplementary-material id="fig5s3sdata1"><label>Figure 5—figure supplement 3—source data 1.</label><caption><title>Contains data and traces for single molecule FRET.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig5-figsupp3-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig5-figsupp3-v3.tif"/></fig></fig-group><p>To assess the impact of the BRC repeat proteins on RAD51 filament formation and stabilization, we utilized a longer DNA substrate (167mer) composed of mixed bases. The reactions were conducted in the absence of calcium to maintain RAD51 ATPase dependent turnover (<xref ref-type="bibr" rid="bib10">Bugreev and Mazin, 2004</xref>). BRC2, BRC2-S1221P, BRC7, BRC7-T1980I, and RAD51 were pre-incubated together followed by the addition of the biotinylated ssDNA substrate (<xref ref-type="fig" rid="fig5">Figure 5D</xref>). The biotin-DNA-RAD51-BRC complexes were then washed extensively, captured on streptavidin magnetic beads, and eluates run on an SDS-PAGE gel. In agreement with the results from our EMSA analyses, BRC2 and BRC7 stabilized RAD51 complex formation on the ssDNA substrate (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 5–6 and lanes 11–12) compared to RAD51 alone (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 2–3). BRC2-S1221P (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 8–9) and BRC7-T1980I (<xref ref-type="fig" rid="fig5">Figure 5E</xref>, lanes 14–15) showed little to no increase in bound RAD51. Consistent with BRC7 playing a larger role in RAD51-ssDNA complex formation (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>), we noted increased levels of RAD51 were stably associated with biotinylated ssDNA in the presence of BRC7 compared to BRC2 (compare lane 12 to lane 6 in <xref ref-type="fig" rid="fig5">Figure 5E</xref>). Interestingly, residual RAD51-ssDNA binding was observed with BRC7-T1980I (compare lane 15 to lane 3 in <xref ref-type="fig" rid="fig5">Figure 5E</xref>) perhaps indicative of a binding mode specific to BRC7 that is not completely diminished by the T1980I mutation.</p><p>To determine how the BRC variants contribute to RAD51 nucleation at single molecule resolution in real-time, we performed a <underline>s</underline>ingle <underline>m</underline>olecule <underline>F</underline>örster <underline>R</underline>esonance <underline>E</underline>nergy <underline>T</underline>ransfer (smFRET) assay. Our smFRET design placed the donor fluorophore (green) in the ssDNA while the acceptor fluorophore (red) was positioned 16 nucleotides from the donor, at the ss/dsDNA junction (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). In this configuration, the flexible ssDNA region brings the donor and acceptor molecules into close proximity leading to efficient energy transfer between the FRET pair and corresponds to a high FRET state when plotted as a FRET histogram (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Upon RAD51 binding, the ssDNA is extended, resulting in an increase in the distance between the donor and acceptor thereby reducing the efficiency of FRET, and a shift to lower FRET states see example of 400 nM RAD51 (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). To observe stimulation of RAD51-ssDNA complexes by the BRC peptides, we utilized a sub-stoichiometric level of RAD51 (20 nM) at which no change in FRET is observed with RAD51 alone (<xref ref-type="fig" rid="fig5">Figure 5F</xref>). Pre-incubation of 20 nM WT BRC2 with 20 nM RAD51 (1:1 ratio) maintained the same FRET state as RAD51 alone. However, WT BRC7 pre-incubated with RAD51 reduced the high FRET signal (E<sub>FRET</sub> = 0.70) to a lower state (E<sub>FRET</sub> = 0.60) indicating that BRC7 can stimulate RAD51 nucleation or filament formation on the ssDNA substrate. Surprisingly, despite a range of concentrations and molar ratios tested, we were unable to detect any change in FRET mediated by WT BRC2. Our results with BRC2 S1221P and BRC7 T1980I agreed with our gel-based analyses as no change in FRET was observed (<xref ref-type="fig" rid="fig5">Figure 5F</xref>, <xref ref-type="fig" rid="fig5s3">Figure 5—figure supplement 3</xref>). Control experiments with all BRC peptides in the absence of RAD51 confirmed no change in the high FRET state (<xref ref-type="fig" rid="fig5s2">Figure 5—figure supplement 2</xref>). Taken together, the data support the hypothesis that S1221P and T1980I harbor a biochemical defect compromising the ability of BRCA2 to bind and stabilize the RAD51 nucleoprotein complex.</p></sec><sec id="s2-6"><title>The full-length BRCA2 T1980I protein binds DNA but exhibits impaired stimulation of RAD51-dependent DNA strand exchange activity</title><p>To further probe the impact of the S1221P and T1980I mutations on BRCA2 functions, we attempted to purify the full-length proteins (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>). Despite extensive troubleshooting, we were unable to purify the full-length S1221P protein due to instability and degradation issues. Purification of full-length T1980I protein was successful (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1A</xref>, lane 3). To evaluate the DNA binding profile of purified T1980I, we performed EMSAs on 3’ Tail, 5’ Tail, ssDNA, and dsDNA substrates (<xref ref-type="fig" rid="fig6s1">Figure 6—figure supplement 1B</xref>). T1980I bound all DNA substrates with comparable affinities to the WT BRCA2 protein.</p><p>We next evaluated whether stimulation of RAD51-mediated DNA strand exchange was impacted by the T1980I variant. We implemented a strategy utilized previously to define the mediator role of wild type BRCA2: (1) we first incubated a 3’ tail DNA substrate with RPA, (2) followed by the addition of wild type BRCA2, or T1980I, simultaneously with RAD51, and (3) finally, a radiolabeled donor dsDNA was added to initiate the DNA strand exchange reaction (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref> and <xref ref-type="fig" rid="fig6">Figure 6A</xref>). Strikingly, T1980I was severely impaired for stimulation of RAD51-mediated DNA strand exchange (<xref ref-type="fig" rid="fig6">Figure 6B and C</xref>). The results corroborate our cell-based findings and define the T1980I biochemical defect as disruption of RAD51 binding leading to a failure to fully stimulate RAD51-ssDNA complex formation and diminished ability to mediate RAD51-dependent DNA strand exchange. Although full-length BRCA2 S1221P protein proved to be intractable to purification, we speculate that stimulation of RAD51-mediated DNA strand exchange activity would be reduced to similar levels due to defects in both RAD51 binding and stabilization of RAD51-ssDNA complexes.</p><fig-group><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>RAD51-mediated DNA strand exchange activity is stimulated by increasing amounts of WT BRCA2 but not T1980I.</title><p>(<bold>A</bold>) Diagram of DNA strand exchange assay. RPA was pre-bound to the 3’ tail DNA substrate for 5 min. Increasing amounts of WT BRCA2 or T1980I protein was then added in combination with RAD51 for 5 min, followed by the addition of radiolabeled donor dsDNA for 30 min. All reactions were incubated at 37 degrees. The reaction was then deproteinized and run on a 6% TAE polyacrylamide gel. (<bold>B</bold>) Autoradiograms of PAGE gels used to analyze the products of DNA strand exchange. Lane 1 is no protein control. Lane 2 is RAD51 in the absence of RPA or BRCA2. (<bold>C</bold>) Quantification of product formation from autoradiogram in (<bold>B</bold>); mean values were plotted. Errors bars represent the S.D. of three biological independent experiments.</p><p><supplementary-material id="fig6sdata1"><label>Figure 6—source data 1.</label><caption><title>Contains original (uncropped) gel image (<xref ref-type="fig" rid="fig6">Figure 6B</xref>) and band quantitation (<xref ref-type="fig" rid="fig6">Figure 6C</xref>).</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig6-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig6-v3.tif"/></fig><fig id="fig6s1" position="float" specific-use="child-fig"><label>Figure 6—figure supplement 1.</label><caption><title>Purified full-length BRCA2 WT and T1980I proteins bind a panel of DNA substrates with equivalent efficiencies.</title><p>(<bold>A</bold>) Stain Free gel (4–15% gradient SDS-PAGE) of full-length 2XMBP-BRCA2 proteins purified from 293T cells. (<bold>B</bold>) EMSAs depicting increasing concentrations of BRCA2 WT and T1980I proteins incubated with 3’ Tail, 5’ Tail, ssDNA, and dsDNA substrates. Percentage of protein-DNA complex was calculated as the free DNA remaining in a lane relative to the protein-free lane (0% complex or 100% free DNA). Error bars are S.D. from 4 (3’tail) and 2 (5’tail) independent experiments.</p><p><supplementary-material id="fig6s1sdata1"><label>Figure 6—figure supplement 1—source data 1.</label><caption><title>Contains original (uncropped) gel images and band quantitation.</title></caption><media mimetype="application" mime-subtype="zip" xlink:href="elife-79183-fig6-figsupp1-data1-v3.zip"/></supplementary-material></p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig6-figsupp1-v3.tif"/></fig></fig-group></sec></sec><sec id="s3" sec-type="discussion"><title>Discussion</title><p>Through a comprehensive analysis of three independent variants located in the BRC repeats of BRCA2, our goals were to not only identify potentially pathogenic variants with important clinical implications for cancer risk in patients, but to also leverage deleterious variants to uncover the specific functions carried out by individual BRC repeats. Our findings reveal that specific BRC repeat mutations within the context of the full-length BRCA2 protein impair critical functions despite the presence of the remaining functional BRC repeats. Our work provides evidence that the BRC7 repeat stimulates RAD51 nucleation/filament stability in a different manner than the BRC2 repeat. We demonstrate that BRC7 alone can bind RAD51 but only under conditions where RAD51 can self-associate, as in the case of a nucleoprotein filament. Collectively, our results with patient-derived missense variants highlight that single amino acid changes in an individual BRC repeat, within the context of the full-length 3418 amino acid BRCA2 protein, substantively impact functions of BRCA2 related to RAD51 binding and regulation during HDR and fork protection (<xref ref-type="fig" rid="fig7">Figure 7</xref>).</p><fig id="fig7" position="float"><label>Figure 7.</label><caption><title>BRCA2 missense variants S1221P (BRC2) and T1980I (BRC7), but not T1346I (spacer BRC2-3).</title><p>(1) exhibit decrease in HDR and fork degradation, (2) disrupt RAD51 binding and (3) fail to stimulate RAD51-ssDNA complex formation and RAD51 filament stability.</p></caption><graphic mimetype="image" mime-subtype="tiff" xlink:href="elife-79183-fig7-v3.tif"/></fig><p>The eight proximal BRC repeats of human BRCA2 bind RAD51 with varying affinities and facilitate the loading and nucleation of RAD51 onto ssDNA. Each BRC repeat comprises a highly conserved motif, FxTASGK, crucial for BRCA2–RAD51 interactions (<xref ref-type="fig" rid="fig1">Figure 1A and B</xref>). Our study has shown that site-specific variants in individual BRC repeats alter the biochemical functions of BRCA2 leading to cellular defects in response to DNA damage providing functional evidence for pathogenicity. Specifically, we found that missense variants located at the third amino acid position in the Fx<bold><underline>T</underline></bold>ASGK motif, S1221P (BRC2) and T1980I (BRC7): (1) disrupt RAD51 binding; (2) do not fully rescue survival in response to chemotherapeutics; (3) diminish RAD51 foci formation; (4) exhibit fork protection defects; (5) fail to stimulate RAD51-ssDNA complex formation; and (6) in the case of T1980I, binds DNA but does not stimulate RAD51-dependent DNA strand exchange (<xref ref-type="fig" rid="fig7">Figure 7</xref>). Our findings emphasize the importance of the serine and threonine residues in the conserved Fx<bold><underline>T</underline></bold>ASGK motif located within each BRC repeat (<xref ref-type="bibr" rid="bib41">Lo et al., 2003</xref>). Similar defects were reported for the BRC4 mutant T1526A and a BRC3 mutant (<xref ref-type="bibr" rid="bib12">Carreira et al., 2009</xref>; <xref ref-type="bibr" rid="bib19">Davies et al., 2001</xref>). The Fx<bold><underline>T</underline></bold>ASGK motif has been noted in other proteins such as RECQL5 and MMS22L, and mutations that disrupt RAD51 binding downregulate HDR and replication fork protection/stability (<xref ref-type="bibr" rid="bib30">Islam et al., 2012</xref>; <xref ref-type="bibr" rid="bib55">Piwko et al., 2016</xref>).</p><p>To the best of our knowledge, we are the first to characterize the BRCA2 T1346I variant, within the context of the full-length protein, found somatically mutated in a colorectal tumor specimen. BRCA2 missense variants located between BRC repeats have been classified as benign in ClinVar and the Breast Information Core (BIC) databases through bioinformatic prediction and familial linkage analysis. We were unable to uncover any defects in the T1346I variant located between BRC2 and BRC3; however, more studies will be required to determine whether other pathogenic variants exist in the spacer regions between the BRC repeats.</p><p>Despite tremendous progress made in the past two decades delineating the explicit functions of the BRCA2 protein, many questions remain regarding the biological significance of multiple RAD51 binding modules located in the BRC repeats and carboxy terminus (S3291) of BRCA2. Furthermore, why does human BRCA2 possess eight BRC repeats whereas organisms such as <italic>Ustilago maydis</italic> and <italic>Caenorhabditis elegans</italic> contain only one BRC repeat (<xref ref-type="bibr" rid="bib36">Kojic et al., 2002</xref>; <xref ref-type="bibr" rid="bib44">Martin et al., 2013</xref>)? The human BRC repeats have been found to interact with RAD51 with varying affinities based on yeast two-hybrid, co-immunoprecipitation, and pull-down assays using tagged purified proteins (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>; <xref ref-type="bibr" rid="bib17">Chen et al., 1999</xref>; <xref ref-type="bibr" rid="bib16">Chen et al., 1998</xref>; <xref ref-type="bibr" rid="bib20">Esashi et al., 2005</xref>; <xref ref-type="bibr" rid="bib68">Thorslund et al., 2007</xref>; <xref ref-type="bibr" rid="bib72">Wong et al., 1997</xref>). The emerging consensus is that BRC1, 2, 3, and 4 bind monomeric RAD51 with high affinity, whereas BRC5, 6, 7, 8 bind weakly. However, BRC5, 6, 7, and 8 significantly stimulate RAD51-ssDNA complex formation implying specific interactions and stabilization of the RAD51 nucleoprotein filament (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). Lastly, the detailed structure, orientation, and regulation of the eight human BRC repeats within the framework of the full-length BRCA2 protein remain unknown.</p><p>We confirmed that BRC1-2, BRC3-4, BRC7-8 and individual BRC1, 2, 4, and 7 repeats bind RAD51 (<xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2A, B</xref>). However, as noted in our previous study (<xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>), BRC5-8 and BRC5-6 do not bind RAD51 in a non-filament form (Figure S5A). Our results agree with prior conclusions from yeast two-hybrid experiments and pull-down interaction studies with GFP-RAD51 in human cells (<xref ref-type="bibr" rid="bib72">Wong et al., 1997</xref>; <xref ref-type="bibr" rid="bib75">Yu et al., 2003</xref>). BRC5 and BRC6 are the least conserved repeats potentially explaining the lack of RAD51 binding (<xref ref-type="bibr" rid="bib6">Bignell et al., 1997</xref>; <xref ref-type="bibr" rid="bib41">Lo et al., 2003</xref>). The lack of BRC7 binding to RAD51 T131P (<xref ref-type="fig" rid="fig4">Figure 4E</xref>) lends support to the hypothesis that the BRC5-8 module interacts specifically with the RAD51 filament, in agreement with our previous data and prior publications (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>; <xref ref-type="bibr" rid="bib15">Chatterjee et al., 2016</xref>). Intriguingly, BRC repeats 1–4 inhibit the ssDNA-dependent ATPase activity of RAD51 whereas BRC repeats 5–8 appear to have no role in this function (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>). Conversely, BRC repeats 5–8 stimulate RAD51-ssDNA complex formation through an unknown mechanism (<xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref>). Our prior work demonstrated that BRC5-8 tethered to the DBD of BRCA2 provided greater functionality than BRC1-4-DBD, and even surprisingly BRC1-8-DBD, in both cell-based and biochemical HDR assays. It remains to be determined why BRC5-8-DBD, lacking the N-terminus and BRC1-4 repeats, demonstrated higher activity than other BRC-DBD fusion proteins. Interestingly, our smFRET data (<xref ref-type="fig" rid="fig5">Figure 5F</xref>) establishes a clear distinction between the two categories of BRC repeats, exemplified by BRC2 and BRC7. Using sub-stoichiometric concentrations of RAD51, we demonstrated that BRC7, unlike BRC2, stabilized RAD51-ssDNA complexes. Little is known regarding the regulatory and structural roles of each BRC repeat, and thus, our smFRET data provides further evidence for differential effects mediated by individual BRC repeats on RAD51 nucleation and stability at single molecule resolution. As our smFRET studies directly measure changes in the distance between two fluorophores at fixed positions along the DNA substrate, we cannot rule out the possibility that BRC7 may facilitate a change in the RAD51-ssDNA conformation unrelated to nucleation/filament formation leading to the lower FRET state. However, given the established role of BRCA2 in facilitating RAD51-ssDNA stability, we favor the conclusion that BRC7 is indeed stimulating RAD51 nucleation and/or filament formation. Future studies using site-directed mutagenesis to systematically inactivate RAD51 binding in each of the BRC repeats, similar to the work described here for patient-derived missense variants, should clarify how the two BRC modules contribute to HDR functions.</p><p>VUS described in the literature are often miscategorized as ‘tumor-associated’ with unknown impact on protein function, and subsequently, unknown association with tumorigenicity. Reliance on software prediction algorithms such as SIFT or PolyPhen to predict pathogenicity, rather than functional assays, may or may not result in correct classification. Uncertainties surrounding VUS interpretation have become a substantial clinical challenge for physicians and genetic counselors attempting to make critical treatment decisions or counsel patients about future cancer risk. Adoption of functional laboratory-based assays into the clinic has been slow due to low throughput, the expertise required for interpretation, and the need for extensive validation utilizing known pathogenic variants. Nonetheless, considerable progress has been made studying variants located in the DBD domain of BRCA2 using the DR-GFP reporter assay or rescue of mouse embryonic stem cell lethality (<xref ref-type="bibr" rid="bib7">Biswas et al., 2011</xref>; <xref ref-type="bibr" rid="bib8">Biswas et al., 2012</xref>; <xref ref-type="bibr" rid="bib9">Biswas et al., 2020</xref>; <xref ref-type="bibr" rid="bib14">Carvalho et al., 2007</xref>; <xref ref-type="bibr" rid="bib22">Farrugia et al., 2008</xref>; <xref ref-type="bibr" rid="bib24">Guidugli et al., 2014</xref>; <xref ref-type="bibr" rid="bib23">Guidugli et al., 2013</xref>). Expanding the repertoire of variants to other domains, as done here for the BRC repeats, will be vital to build a comprehensive molecular understanding of how specific defects lead to BRCA2 dysfunction. The utility of patient-derived missense variants with accompanying clinical data lies not only in their potential to improve cancer risk prediction models but to also provide clinically relevant mutations that can further elucidate the underlying biology of the BRCA2 protein. Importantly, rigorous biochemical and genetic assays hold promising potential to differentiate pathogenic from benign BRCA2 variants. Moreover, functional assays may be the only recourse to advise patients with rare variants concerning their future cancer risk.</p><p>Given the total number of BRCA2 variants that currently exist (15,079 in ClinVar accessed 2022-07-12) and will continue to increase as genome sequencing efforts become incorporated into clinical care, large-scale studies will be necessary to evaluate functionality. However, the specific functions of BRCA2 required for tumor suppression have not been rigorously identified. Our assumption that canonical HDR functions (RAD51 loading/filament stabilization) underlie BRCA2’s role in tumor suppression seems likely but requires definitive proof. BRCA2 is a large, complex protein that paradoxically is required for cellular viability, and yet, its loss in somatic human cells drives tumor initiation and/or progression. For large-scale testing of BRCA2 VUS to be successful in predicting cancer risk, we need to carefully consider which specific functions impart tumor suppression. Will the assay use in large-scale studies measure rescue of viability, HDR, fork protection, gap suppression, or some other attribute? To date, there is no one assay that directly measures the tumorigenic capacity of BRCA2 mutations as has been done for certain oncogenes. We favor the idea that in-depth biochemical and cellular analysis of patient derived BRCA2 variants with known clinical outcomes will help elucidate the features required for tumor suppressor functions. Because most human cell lines are not viable in the absence of the BRCA2 protein, the unique advantage of the DLD1 BRCA2<sup>-/-</sup> cell system is that it provides us with a cellular tool to perform complementation studies with both benign and deleterious variants. The variants can be assessed for response to clinically relevant chemotherapeutic agents such as cisplatin and PARP inhibitors. Leveraging the transfection efficiency and overexpression capabilities of human 293T cells, we can then purify the full-length variant proteins and assess biochemical functions to understand the altered molecular mechanisms (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>).</p><p>Clinical integration of functional assays into the genetic counseling setting is an important goal but should be undertaken with caution until we fully understand how specific variants impact the tumor suppressor functions of BRCA2. Our study demonstrated that novel pathogenic variants exist not only in the DBD domain of BRCA2 but also in the BRC region leading to defects in RAD51 binding, activity, and subsequent HDR deficiencies. Mechanistic studies leveraging patient variants will continue to reveal the many functions of BRCA2.</p></sec><sec id="s4" sec-type="materials|methods"><title>Materials and methods</title><sec id="s4-1"><title>Sequence alignment and molecular modeling of BRC repeats</title><p>BRCA2 amino acids sequences from 9 different organisms were obtained from Uniprot Knowledgebase database <ext-link ext-link-type="uri" xlink:href="https://www.uniprot.org/">https://www.uniprot.org/</ext-link> (<xref ref-type="bibr" rid="bib18">Consortium, 2011</xref>). Alignments were done with ClustalIX (<xref ref-type="bibr" rid="bib38">Larkin et al., 2007</xref>) <ext-link ext-link-type="uri" xlink:href="http://www.ch.embnet.org/software/ClustalW.html">http://www.ch.embnet.org/software/ClustalW.html</ext-link>, and <ext-link ext-link-type="uri" xlink:href="https://itservices.cas.unt.edu/software/bioedit725">Bioedit</ext-link> html (<xref ref-type="bibr" rid="bib26">Hall, 1999</xref>). SnapGene software was used for BRC2, BRC4 and BRC7 sequence alignment (&gt;60% threshold for shading). The UniprotKB codes of the sequences from different organisms were: <bold>P51587</bold> <italic>Homo sapiens (Human</italic>); Q<bold>9W157</bold> <italic>Drosophila melanogaster (Fruit fly);</italic> <bold>P97929</bold> <italic>Mus musculus (Mouse);</italic> <bold>Q864S8</bold> <italic>Felis catus (Cat);</italic> <bold>O35923</bold> <italic>Rattus norvegicus (Rat);</italic> <bold>A5A3F7</bold> <italic>Strongylocentrotus purpuratus (Purple sea urchin);</italic> <bold>A4ZZ89</bold> <italic>Monodelphis domestica (Gray short-tailed opossum);</italic> <bold>Q8MKI9</bold> <italic>Canis lupus familiaris (Dog) (Canis familiaris);</italic> <bold>A4ZZ90</bold> <italic>Xenopus tropicalis (Western clawed frog) (Silurana tropicalis</italic>).</p><p>Models are computed by the SWISS-MODEL server homology modelling pipeline (<xref ref-type="bibr" rid="bib71">Waterhouse et al., 2018</xref>), which relies on ProMod3 (<xref ref-type="bibr" rid="bib64">Studer et al., 2021</xref>), an in-house comparative modelling engine based on OpenStructure (<xref ref-type="bibr" rid="bib5">Biasini et al., 2013</xref>). Swiss-Model Expasy server was used to model BRC2 and BRC7 against BRC4 in the PDB structure 1N0W (<xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref>; <xref ref-type="bibr" rid="bib71">Waterhouse et al., 2018</xref>). The modeled BRC2 and BRC7 structures had QMEAN Z-scores greater than –4 (0.06 and –1.42 respectively) and were considered good quality models.</p><p>The PyMOL Molecular Graphics System, Version 1.3 Schrödinger, LLC. was used to visualize the BRC repeat aligned with the 1N0W structure to look at predicted interactions with RAD51. BRC residues were mutated using the mutagenesis tool and rotamers with a frequency score greater than 10% were analyzed and the least number of clashes were visualized.</p></sec><sec id="s4-2"><title>Constructs</title><p>Point mutations S1221P (3663 bp), T1346I (4038 bp), and T1980I (5940 bp) were cloned into the pBluescript BRCA2 (1–5286 bp) and pUC57 BRCA2 (2141–9117 bp) sequences, respectively, via site-directed mutagenesis. The BRCA2 segments were then subcloned into the phCMV1 mammalian expression vector using NotI and EcoRV restriction enzymes for the S1221P and T1346I insert and SbfI and AgeI for the T1980I insert. We verified the putative recombinant clones through restriction digestion and sequencing analysis. The previously described 2XMBP tag (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>) was placed in-frame at the N-terminus of all proteins separated by an Asparagine linker and the PreScission Protease cleavage sequence.</p></sec><sec id="s4-3"><title>Cell culture</title><p>All culture media was supplemented with 10% fetal bovine serum (FBS). HEK293T cells were cultured in DMEM <xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>; DLD1 cells were cultured in RPMI (<xref ref-type="bibr" rid="bib29">Hucl et al., 2008</xref>) (Horizon Discovery). Transient transfections were carried out with Turbofect (Thermo Scientific) (2 μg of DNA, 6-well plate) in HEK293T cells and with JetOptimus (Polyplus Transfection) in DLD1 cells following the manufacture’s protocol. Calcium phosphate transfection (25 μg of DNA per 15 cm<sup>2</sup> plate, see BRCA2 purification section) was used for large scale purifications in HEK293T cells (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>). All cell lines were tested regularly for mycoplasma (Mycoalert, Lonza) and authenticated through ATCC STR profiling.</p></sec><sec id="s4-4"><title>Generation of stable cell lines</title><p>Human colorectal adenocarcinoma DLD-1 BRCA2<sup>-/-</sup> cells (Horizon Discovery, originally generated by <xref ref-type="bibr" rid="bib29">Hucl et al., 2008</xref>) were stably transfected with 2 μg of DNA using Lipofectamine3000 (Invitrogen). After 48 hr, the cells were trypsinized and diluted 1:2, 1:4, and 1:8 into 100 mm plates containing 1 mg/mL G418. Single cell colonies were picked into 96-well plates and subsequently cultured into 24-well plates, 12-well plates, and 6-well plates. Positive clones were isolated, and protein expression was detected by western blot and immunofluorescence analyses.</p></sec><sec id="s4-5"><title>Western blots and amylose pulldowns</title><p>Human embryonic kidney HEK293T cells 70% confluent in 6 well plates were transiently transfected with 0.5 μg or 1 μg of the phCMV1 mammalian expression vector containing a 2XMBP fusion to the full-length or partial cDNA of BRCA2 using TurboFect reagent (Thermo Scientific) (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>). 0.5 μg of 2XMBP tag alone or untransfected cells were used as negative controls. The cells were lysed 48 hr after transfection in 100 μL of lysis buffer: 50 mM HEPES (pH 7.5), 250 mM NaCl, 5 mM EDTA, 1% Igepal CA-630, 3 mM MgCl<sub>2</sub>, 10 mM DTT and protease inhibitor cocktail (Roche). Cell extracts were batch bound to amylose resin (NEB) for 2 hr to capture the 2XMBP tagged BRCA2 proteins. Total cellular lysate aliquots were taken before batch binding for protein expression analysis. Total cellular lysates and amylose pulldown samples were run on a 4–15% gradient SDS-PAGE TGX stain-free gel (Bio-Rad 456–8086) and transferred to an Immobilon-P membrane (Merck Millipore IPVH00010) in 1 X Tris/glycine buffer (diluted from 10 X Tris/glycine buffer, Bio-Rad 161–0771). The membrane was blocked in 5% milk in 1 X TBS-T (diluted from 10 X TBS-T: 0.1 M Tris base, 1.5 M NaCl, 0.5% Tween-20). Washes and antibody incubations were done with 1 X TBS-T. Primary mouse antibodies against MBP (NEB E8032L, 1:5000) and RAD51 (Novus Biologicals 14b4, 1:1000) and primary rabbit antibody against BRCA2 (Abcam, ab27976) were used for western blotting. Membranes were incubated with secondary mouse and rabbit antibodies (HRP-conjugated, Santa Cruz Biotechnology sc-516102 and sc-2004, respectively). The western blots were visualized using Clarity Western ECL substrate (Bio-Rad 170–5061) for three minutes and scanning with a ChemiDocMP imaging system (Bio-Rad). For amylose pull-down assays in DLD1 stable cells, three 15 cm<sup>2</sup> plates were used.</p><p>BRC2, BRC7, BRC2-S1221P and BRC7-T1980I synthetic peptides (see <xref ref-type="table" rid="table1">Table 1</xref> below for amino acid sequences) were ordered from Pierce, resuspended in BRCA2 storage buffer (50 mM HEPES pH 8.2, 450 mM NaCl, 0.5 mM EDTA, 10% Glycerol, 1 mM DTT). In vitro amylose pull-down assays were performed in binding buffer ‘B’: 50 mM HEPES (pH 7.5), 250 mM NaCl, 0.5 mM EDTA, and 1 mM DTT. Purified 2XMBP fusion proteins (2 µg) were incubated with 1 µg purified RAD51 for 30 min at 37 °C and then batch bound to 30 µL of amylose resin for 1 hr at 4 °C. The complexes were washed with buffer B containing 0.5% Igepal CA-630/0.1% Triton X-100, eluted with 30 µL of 10 mM maltose in buffer B, Laemmli sample buffer was added, samples were heated at 54 °C for 4 min, and loaded onto a 4–15% gradient SDS-polyacrylamide gel (Bio-Rad TGX Stain-Free gel). The gel was run for 1 hr at 130 Volts. The proteins were visualized using Stain-Free imaging on a ChemiDocMP system (Bio-Rad). RAD51 protein was visualized by staining with SyproOrange (Invitrogen). The Stain-Free protein bands were quantified using Image Lab software (version 6.1 Bio-Rad).</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Amino acid sequences of synthesized peptides.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">PEPTIDES</th><th align="left" valign="top">AMINO ACID SEQUENCES</th></tr></thead><tbody><tr><td align="left" valign="top">BRC2</td><td align="left" valign="top">NEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIEN</td></tr><tr><td align="left" valign="top">BRC2-S1221P</td><td align="left" valign="top">NEVGFRGFY<bold>P</bold>AHGTKLNVSTEALQKAVKLFSDIEN</td></tr><tr><td align="left" valign="top">BRC7</td><td align="left" valign="top">SANTCGIFSTASGKSVQVSDASLQNARQVFSEIED</td></tr><tr><td align="left" valign="top">BRC7-T1980I</td><td align="left" valign="top">SANTCGIFS<bold>I</bold>ASGKSVQVSDASLQNARQVFSEIED</td></tr></tbody></table></table-wrap><p>For competition assays, synthetic BRC peptides were pre-incubated with RAD51 for 30 min. In parallel, 2XMBP fusion proteins expressed in HEK293T cells were pulled down with amylose resin for 30 min as described above. The 2XMBP fusion proteins bound to amylose resin were washed with buffer B containing 1 M NaCl to disrupt non-specific or weak protein interactions.</p></sec><sec id="s4-6"><title>Immunofluorescence imaging</title><p>Stable cell clones generated from DLD-1 BRCA2<sup>-/-</sup> cells were grown on coverslips at 10<sup>5</sup> cells/well in a 24-well plate for 24 hr. Cells were washed twice with 1 X PBS, fixed in 1% paraformaldehyde-2% sucrose in 1 X PBS for 15 min at room temperature, washed twice with 1 X PBS, permeabilized with methanol for 30 min at –20 °C, then washed two more times with 1 X PBS, and finally incubated with 0.5% triton in PBS for 10 min. Samples were blocked with 5% BSA in 1 X PBS for 30 min at room temperature followed by subsequent incubation with primary antibodies against MBP (NEB E8032L, 1:200) and RAD51 (Proteintech 14961–1-AP, 1:100 or Abcam ab63801) in 5% BSA-0.05% TritonX-100 at 4 °C overnight. The next day, cells were washed three times with 1 X PBS and incubated with goat anti-rabbit and anti-mouse secondary antibodies conjugated to the fluorophores Alexa-488 and Alexa-546 (Thermo Fisher Scientific A11034 and A11003, respectively; 1:1000). Coverslips were washed three times with 1 X PBS, incubated with 30 nM DAPI for 5 min and mounted on slides with FluorSave reagent (Calbiochem 345789). Immunofluorescence images were taken using a Keyence BZ-X800E Fluorescent Microscope with a 40 X or 60 X objective lens. Cells were either untreated (control) or irradiated at 12 Gy using an X-Rad 320 Biological Irradiator and cells were collected at 6 and 30 hr post irradiation for immunofluorescence imaging.</p></sec><sec id="s4-7"><title>Clonogenic survival assay</title><p>Stable cell clones generated from DLD-1 BRCA2<sup>-/-</sup> cells were serially diluted and seeded into six-well plates at concentrations of 100 and 500 cells per well in triplicate for plating efficiency. Simultaneously, cells were seeded for treatment in six-well plates at 1000 and 10,000 cells per well in triplicate. Twenty-four hours after seeding, cells were treated with the indicated concentrations of Mitomycin C (1.5 mM stock in water), Cisplatin (100 mM stock in DMSO) for 1 hr in serum-free media and Olaparib (50 mM stock in DMSO) or BMN (10 nM stock in DMSO) for durations of 24 hr. Following treatment, media was aspirated, and cells were washed with 1 X PBS and re-fed with fresh media containing FBS. Cells were cultured for 14 days to allow colony formation, after which they were stained with crystal violet solution (0.25% crystal violet, 3.5% formaldehyde, 72% methanol). Colonies containing 50 or more cells were scored and surviving fractions were determined.</p><sec id="s4-7-1"><title>Clover Lamin A HDR assay</title><p>Cells grown on coverslips in six-well plates (5x10<sup>5</sup> cells/well) were transfected with sgRNA plasmid targeting Lamin A (pX330-LMNA-gRNA1, addgene 122507) and donor plasmid (pCR2.1 Clover-LMNA Donor, addgene 122507) with 2.4 µg and 0.6 µg of DNA, respectively, using JetOptimus (Polyplus). Single vectors were transfected as negative controls. Cells were imaged alive 96 hr post-transfection using a Keyence BZ-X800E Fluorescent Microscope or were fixed with 1% PFA/2% Sucrose for 10 min and permeabilized with PBS-0.5% Triton buffer for 5 min. Gene targeting efficiency was determined by counting with Cell Profiler (Positive nuclei pipeline, threshold 0.25 for clover channel intensity) the percentage of Clover-positive cells using DAPI (Thermo Fisher 40 X objective, fixed cells) or NucRed Live 647 ReadyProbes Reagent (Thermo Fisher 20 X objective, live cells). Four independent experiments were performed and at least 500 cells were counted in each experiment. Data was plotted and represented in Graph Pad version 9.</p></sec><sec id="s4-7-2"><title>DNA fiber combing (DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xpro.2022.101371">10.1016</ext-link> <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xpro.2022.101371">/j</ext-link><ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1016/j.xpro.2022.101371">.xpro.2022.101371</ext-link>)</title><p>Stable cell clones generated from DLD-1 BRCA2<sup>-/-</sup> cells were grown in 6 cm plates overnight and were 30% confluency at the time of treatment. Cells were treated with 100 μM CldU in cell culture media, for 30 min, washed three times with PBS and treated with 100 μM ldU for 30 min, followed by three PBS washes. Cells were then treated with 4 mM hydroxyurea (HU) in water, for 5 hr. After the 5 hr treatment, 1.5x10<sup>5</sup> cells were harvested, washed in PBS and resuspended in trypsin. 1.2% low melting agarose was added to each sample and an agarose plug was allowed to solidify using a mold at 4 °C for 1 hr. Plugs were then incubated overnight in ESP buffer (10% (w/v) Sarcosyl in 0.5 M pH = 8 EDTA with 20 mg/mL proteinase K) at 50 °C. The next day plugs received 3 one hour washes followed by one 3.5 hr wash in TE10.1 buffer (10 mM Tris-HCL, 1 mM pH = 8 EDTA). Plugs were immersed in 0.5 M MES pH = 7.4 solution and incubated for 20 min at 68 °C, followed by 10 min at 42 °C. β-agarase was added to each sample and incubated overnight at 42 °C. Each DNA solution was added to a disposable reservoir containing 0.5 M MES pH = 7.4. A pre-coated, silanized glass coverslip was submerged into each fibers solution and removed at a slow constant rate. These fibers were stretched and straightened while binding the coverslip through a combing procedure using the FiberComb Molecular Combing System (Genomic Vision). Combed coverslips were then incubated at 65 °C for 2 hr. Fiber coated coverslips were then submerged in a denaturing solution (0.5 M NaOH, 1 M NaCl) for 8 min, washed three times in PBS and dehydrated in 70% and then 100% ethanol. Coverslips were blocked with 5% BSA in PBS for 30 min at 37 °C. Each coverslip was incubated with primary antibodies diluted in 5% BSA for 1 hr. Primary antibodies used were mouse anti-BrdU (BD Biosciences 347580, 1:10) and rat anti-BrdU (Abcam ab6326, 1:40). Secondary antibodies used were goat anti-rat Cy5 (Abcam ab6565, 1:100) and sheep anti-mouse Cy3 (Sigma C2181, 1:100) and were incubated for 30 min. All antibody incubations were at 37 °C in a wet chamber. Coverslips were protected from the light and mounted using Prolong Diamond Antifade (P36970). Fluorescence images were taken using a Keyence BZ-X800E Fluorescent Microscope with a 60 X oil objective lens. Using ImageJ software, the length of each DNA fiber tract was measured and a ratio of IdU/CldU calculated, with a minimum of 100 fibers (Idu and CldU tract) measured for each sample (for further details see <xref ref-type="bibr" rid="bib48">Moore et al., 2022</xref>).</p></sec><sec id="s4-7-3"><title>Protein purification (doi: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1038%2Fnature09399">10.1038/nature09399</ext-link> and DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/978-1-4939-0992-6_17">10.1007/978-1-4939-0992-6_17</ext-link>)</title><p>2XMBP- BRC2, BRC7, S1221P-BRC2, T1980I-BRC7 or BRCA2 wild-type, S1221P, T1346I, and T1980I (see <xref ref-type="table" rid="table2">Table 2</xref> below for amino acid sequences) were purified as described for the purification full-length BRCA2 protein (<xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Lahiri and Jensen, 2021</xref>). The phCMV1 constructs with human BRCA2 cDNA and 2XMBP tag were transiently transfected using CaPO<sub>4</sub> precipitation into HEK293T cells and harvested 30 hr post-transfection. Cell extracts were batch bound to amylose resin overnight. Bound proteins tagged with 2XMBP were eluted with 100 mM maltose and 8 mM glucose, loaded onto a HiTrap Q column, and step eluted at 450 mM NaCl. Fractions with peak protein concentrations were collected and snap frozen in liquid nitrogen and stored at –80 °C. Selected fractions were combined and concentrated with an Amicon Pro Purification system (10 kDa, Millipore). All samples were stored at –80 °C. Purified proteins were visualized on a 4–15% gradient SDS-PAGE TGX Stain-Free gel (Bio-Rad 456–8086) and then stained with Coomassie blue (Bio-Rad 1610786). Protein preparations were quantified by running varying levels of protein on a Stain-Free gel and quantifying band intensity with Bio-Rad Image Lab software. Samples were also quantified at an absorbance of 280 nm using a NanoDrop spectrophotometer (for further details see <xref ref-type="bibr" rid="bib32">Jensen, 2014</xref>; <xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>). RPA and RAD51 were purified as described previously (<xref ref-type="bibr" rid="bib2">Anand et al., 2018</xref>; <xref ref-type="bibr" rid="bib66">Subramanyam and Spies, 2018</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Amino acid sequences of BRC purified proteins.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">CONSTRUCTS</th><th align="left" valign="top">AMINO ACID SEQUENCE</th></tr></thead><tbody><tr><td align="char" char="." valign="top">2xMBP BRC2</td><td align="left" valign="top">YLTDENEVGFRGFYSAHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISL*</td></tr><tr><td align="char" char="." valign="top">2xMBP BRC2-S1221P</td><td align="left" valign="top">YLTDENEVGFRGFY<bold>P</bold>AHGTKLNVSTEALQKAVKLFSDIENISEETSAEVHPISL*</td></tr><tr><td align="char" char="." valign="top">2xMBP BRC4</td><td align="left" valign="top">RDEKIKEPTLLGFHTASGKKVKIAKESLDKVKNLFDEKEQGTSEI*</td></tr><tr><td align="char" char="." valign="top">2xMBP BRC4-T1526A</td><td align="left" valign="top">RDEKIKEPTLLGFH<bold>A</bold>ASGKKVKIAKESLDKVKNLFDEKEQGTSEI*</td></tr><tr><td align="char" char="." valign="top">2xMBP BRC7</td><td align="left" valign="top">GKLHKSVSSANTCGIFSTASGKSVQVSDASLQNARQVFSEIEDSTKQ*</td></tr><tr><td align="char" char="." valign="top">2xMBP BRC7-T1980I</td><td align="left" valign="top">GKLHKSVSSANTCGIFS<bold>I</bold>ASGKSVQVSDASLQNARQVFSEIEDSTKQ*</td></tr></tbody></table></table-wrap></sec></sec><sec id="s4-8"><title>Electrophoretic mobility shift assay</title><p>RAD51 (10 nM) was pre-incubated with 2XMBP BRC2, BRC2-S1221P, BRC7 and BRC7-T1980I peptides at the indicated concentrations (0, 0.25, 0.5, 1, 2 µM) for 15 min, followed by addition of ssDNA (Oligo dT40 labeled with <sup>32</sup>P at the 5’ end, 400 pM) in buffer 25 mM TrisOAc (pH 7.5), 10 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 0.1 µg/µL BSA, 2 mM ATP, and 1 mM DTT. The mixture was incubated 45 min at 37 °C, as indicated.</p><p>The following oligonucleotides (see <xref ref-type="table" rid="table3">Table 3</xref> below) were utilized to test BRCA2 WT and T1980I full-length binding. RJ-167-mer and RJ-5’Tail-167mer were radiolabeled with <sup>32</sup>P at the 5′-end using T4 Polynucleotide Kinase (NEB). To generate the 3′ Tail and dsDNA DNA substrates, RJ-167-mer and RJ-167-mer complementary were annealed at a 1:1 molar ratio to RJ-PHIX-42–1, respectively. To generate the 5′ Tail DNA substrate, RJ-5’Tail-167mer was annealed at a 1:1 molar ratio to RJ-PHIX-42–1.</p><table-wrap id="table3" position="float"><label>Table 3.</label><caption><title>Oligonucleotide sequences.</title></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Oligonucleotides</th><th align="left" valign="top">Sequence</th></tr></thead><tbody><tr><td align="left" valign="top">RJ-167-mer</td><td align="left" valign="top"><named-content content-type="sequence">5′-CTG CTT TAT CAA GAT AAT TTT TCG ACT CAT CAG AAA TAT CCG TTT CCT ATA TTT ATT CCT ATT ATG TTT TAT TCA TTT ACT TAT TCT TTA TGT TCA TTT TTT ATA TCC TTT ACT TTA TTT TCT CTG TTT ATT CAT TTA CTT ATT TTG TAT TA TCC TTA TCT TAT TTA-3′</named-content></td></tr><tr><td align="left" valign="top">RJ-5’Tail-167mer</td><td align="left" valign="top"><named-content content-type="sequence">5’-ATT TAT TCT ATT CCT CTT TAT TTT CTC TGT TTA TTC ATT TAC TTA TTT TGT ATT AAT TTC CTA TAT TTT TTA CTT GTA TTT CTT ATT CAT TTA CTT ATT TTG TAT TAT CCT TAT TTA TAT CCT TTC TGC TTT ATC AAG ATA ATT TTT CGA CTC ATC AGA AAT ATC CG-3’</named-content></td></tr><tr><td align="left" valign="top">RJ-167-mer complementary</td><td align="left" valign="top"><named-content content-type="sequence">5’-TAA ATA AGA TAA GGA TAA TAC AAA ATA AGT AAA TGA ATA AAC AGA GAA AAT AAA GTA AAG GAT ATA AAA AAT GAA CAT AAA GAA TAA GTA AAT GAA TAA AAC ATA ATA GGA ATA AAT ATA GGA AAC GGA TAT TTC TGA TGA GTC GAA AAA TTA TCT TGA TAA AGC AG-3’</named-content></td></tr><tr><td align="left" valign="top">RJ-PHIX-42–1</td><td align="left" valign="top"><named-content content-type="sequence">5′-CGG ATA TTT CTG ATG AGT CGA AAA ATT ATC TTG ATA AAG CAG-3′</named-content></td></tr></tbody></table></table-wrap><p>2XMBP-BRCA2 wild-type and T1980I proteins were incubated at the indicated concentrations with 400 pM of the radiolabeled DNA substrate for 30 min at 37 °C. The reactions were resolved by electrophoresis on a 6% polyacrylamide gel in 1 X TAE (40 mM Tris–acetate [pH 7.5], 0.5 mM EDTA) buffer for 90 min at 80 Volts. The gel was then dried onto DE81 paper and exposed to a PhosphorImager screen overnight. The screen was scanned on a Molecular Dynamics Storm 840 PhosphorImager and bands were quantified using ImageLab software. The percentage of protein-DNA complexes was calculated as the free radiolabeled DNA remaining in a given lane relative to the protein-free lane, which defined the value of 0% complex, or 100% free DNA.</p></sec><sec id="s4-9"><title>Biotin DNA pulldowns</title><p>The 2XMBP-BRC purified proteins (80 nM) were incubated with 0, 50, or 100 nM of purified RAD51 for 10 min at 37 °C in Buffer ‘S’: 25 mM TrisOAc (pH 7.5), 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 0.1 µg/µL BSA, 2 mM ATP, and 1 mM DTT. Then 1 nM of the biotinylated ssDNA was added for 10 min at 37 °C. The ssDNA oligonucleotide substrate, RJ-167-mer, was synthesized with a 5’ biotin modification and PAGE purified by IDT (Ultramer). Final volumes were normalized with storage buffer as needed. The DNA-protein complexes were then captured by adding 2.5 µL of pre-washed MagnaLink Streptavidin magnetic beads (SoluLink) in buffer SW (Buffer S supplemented with 0.1% Igepal CA-630 and 0.5% Triton X-100). The bead-DNA-protein complexes were rotated at 25 °C for 5 min and then washed 3 X with buffer SW (lacking 2 mM ATP), resuspended in 20 µL laemmli sample buffer, heated at 54 °C for 4 min, and loaded onto a 4–15% gradient SDS-PAGE gel. The amount of RAD51 protein bound and eluted from the biotinylated DNA was determined by western blot using a monoclonal antibody specific to human RAD51 (14B4, Novus).</p></sec><sec id="s4-10"><title>Single molecule Förster resonance energy transfer (smFRET)</title><p>All reactions were performed at room temperatures in imaging buffer consisting of 50 mM Tris-HCl, pH 8.0, 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 2 mM ATP, 0.1 mg/ml BSA, 25% glucose, Trolox and 1% Gloxy (80% of imaging buffer, 20% catalase and 10 mg glucose oxidase) as described in <xref ref-type="bibr" rid="bib43">Marsden et al., 2016</xref>. Twenty nM BRC peptides were pre-incubated with 20 nM RAD51 in a 1:1 ratio for 15 min at 37 °C followed by the addition of the protein complexes to 300 pM DNA that was tethered to a PEG-coated quartz surface through biotin-neutravidin linkage. smFRET assays were performed as described in <xref ref-type="bibr" rid="bib43">Marsden et al., 2016</xref>; <xref ref-type="bibr" rid="bib56">Rothenberg and Ha, 2010</xref>. Briefly, a custom-built optical imaging platform in reference to Olympus IX70 inverted microscope was used, which was coupled to a 532 (10 mWatts) and a 640 (10 mWatts) nm solid -state lasers to excite the sample in the TIRF mode. Photons collected from the Cy3 and Cy5 fluorophores were then imaged on to a single EMCCD camera (Andor iXon3) with images acquired at 33 Hz and EM gain set to 300. Data consisting of 500 frames were recorded with each frame having an exposure time of 30ms and analyzed as indicated in Marsden et al. Matlab (version R2020b) was used to view and analyze the FRET trajectories. The FRET histograms were generated using a sample size of at least 250 single molecule trajectories and the representative histograms did not include zero FRET values or photobleached portions of the FRET trajectories. Origin (version 2021) was used to plot the histograms and the FRET trajectories.</p><sec id="s4-10-1"><title>DNA strand exchange (DOI: <ext-link ext-link-type="uri" xlink:href="https://doi.org/10.1007/978-1-0716-0644-5_8">10.1007/978-1-0716-0644-5_8</ext-link>)</title><p>All DNA substrates were obtained PAGE purified from IDT. The 3’ Tail DNA substrate was generated by annealing RJ-167-mer to RJ-PHIX-42–1 at a 1:1 molar ratio. The dsDNA donor was generated by first radiolabeling RJ-Oligo1 (<named-content content-type="sequence">5’-TAA TAC AAA ATA AGT AAA TGA ATA AAC AGA GAA AAT AAA G-3’</named-content>) with <sup>32</sup>P (T4 Polynucleotide Kinase) on the 5’-end and annealing it to RJ-Oligo2 (<named-content content-type="sequence">5’-CTT TAT TTT CTC TGT TTA TTC ATT TAC TTA TTT TGT ATT A-3’</named-content>) at a 1:1 molar ratio. The assay buffer contained: 25 mM TrisOAc (pH 7.5), 1 mM MgCl<sub>2</sub>, 2 mM CaCl<sub>2</sub>, 0.1 µg/µL BSA, 2 mM ATP, and 1 mM DTT. All pre-incubations and reactions were at 37 °C. The DNA substrates and proteins were at the following concentrations unless otherwise indicated in the figure legend: RPA (0.1 µM); RAD51 (0.4 µM); 3’ tail (4 nM molecules); and dsDNA (4 nM molecules). The 3’ Tail DNA was incubated first with RPA for 5’, followed by the addition of BRCA2 WT or T1980I proteins and RAD51, and finally, the radiolabeled donor dsDNA was added for 30 min. Where proteins were omitted, storage buffer was substituted. The reaction was terminated with Proteinase K/0.5% SDS for 10 min. The reactions were loaded on a 6% polyacrylamide gel in TAE buffer and electrophoresis was at 60 V for 80 min. The gel was then dried onto DE81 paper and exposed to a PhosphorImager screen overnight. The percentage of DNA strand exchange product was calculated as labeled product divided by total labeled input DNA in each lane (for further details see <xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref>; <xref ref-type="bibr" rid="bib37">Lahiri and Jensen, 2021</xref>).</p></sec></sec><sec id="s4-11"><title>Antibodies</title><table-wrap id="inlinetable1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="top">Antibody</th><th align="left" valign="top">Company</th><th align="left" valign="top">Catalog Number, RRID</th></tr></thead><tbody><tr><td align="left" valign="top">MBP</td><td align="left" valign="top">NEB</td><td align="left" valign="top">Cat# E8032L</td></tr><tr><td align="left" valign="top">BRCA2</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab27976</td></tr><tr><td align="left" valign="top">Rabbit Anti-BRCA2 Nt</td><td align="left" valign="top">Bethyl Laboratories</td><td align="left" valign="top">Cat# A303-434</td></tr><tr><td align="left" valign="top">PALB2</td><td align="left" valign="top">Bethyl Laboratories</td><td align="left" valign="top">Cat# A301-246A</td></tr><tr><td align="left" valign="top">RAD51</td><td align="left" valign="top">Proteintech</td><td align="left" valign="top">Cat#14961–1-AP, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2177083">AB_2177083</ext-link></td></tr><tr><td align="left" valign="top">RAD51</td><td align="left" valign="top">Novus Biologicals</td><td align="left" valign="top">Cat# NB 100–148, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_350083">AB_350083</ext-link></td></tr><tr><td align="left" valign="top">RAD51</td><td align="left" valign="top">Abcam ab63801</td><td align="left" valign="top">Cat# ab63801, RRID: <ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1142428">AB_1142428</ext-link></td></tr><tr><td align="left" valign="top">BrdU-Mouse</td><td align="left" valign="top">BD Biosciences</td><td align="left" valign="top">Cat# 247580</td></tr><tr><td align="left" valign="top">BrdU-Rat</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab6326 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_305426">AB_305426</ext-link></td></tr><tr><td align="left" valign="top">m-IgGκ BP-HRP Antibody</td><td align="left" valign="top">Santa Cruz Biotechnology</td><td align="left" valign="top">Cat# sc-516102, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687626">AB_2687626</ext-link></td></tr><tr><td align="left" valign="top">goat anti-rabbit IgG-HRP antibody</td><td align="left" valign="top">Santa Cruz Biotechnology</td><td align="left" valign="top">Cat# sc-2004, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_631746">AB_631746</ext-link></td></tr><tr><td align="left" valign="top">Goat anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488</td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">Cat# A-11034, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2576217">AB_2576217</ext-link></td></tr><tr><td align="left" valign="top">Goat anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 546</td><td align="left" valign="top">Thermo Fisher Scientific</td><td align="left" valign="top">Cat# A-11003, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534071">AB_2534071</ext-link></td></tr><tr><td align="left" valign="top">Goat anti-Rat Cy5</td><td align="left" valign="top">Abcam</td><td align="left" valign="top">Cat# ab6565 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_955063">AB_955063</ext-link></td></tr><tr><td align="left" valign="top">Sheep anti-mouse Cy3</td><td align="left" valign="top">Sigma</td><td align="left" valign="top">Cat# C2181 RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_258785">AB_258785</ext-link></td></tr></tbody></table></table-wrap></sec></sec></body><back><sec sec-type="additional-information" id="s5"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn><fn fn-type="COI-statement" id="conf2"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Conceptualization, Data curation, Formal analysis, Funding acquisition, Validation, Investigation, Visualization, Methodology, Writing – original draft, Project administration, Writing – review and editing</p></fn><fn fn-type="con" id="con2"><p>Formal analysis, Investigation, Visualization, Methodology, Writing – original draft, Writing – review and editing</p></fn><fn fn-type="con" id="con3"><p>Data curation, Formal analysis, Investigation, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con5"><p>Data curation, Formal analysis, Investigation, Visualization, Methodology, Writing – review and editing</p></fn><fn fn-type="con" id="con6"><p>Investigation, Writing – review and editing</p></fn><fn fn-type="con" id="con7"><p>Data curation, Funding acquisition, Writing – review and editing</p></fn><fn fn-type="con" id="con8"><p>Conceptualization, Formal analysis, Supervision, Funding acquisition, Investigation, Methodology, Writing – original draft, Writing – review and editing</p></fn></fn-group></sec><sec sec-type="supplementary-material" id="s6"><title>Additional files</title><supplementary-material id="transrepform"><label>Transparent reporting form</label><media xlink:href="elife-79183-transrepform1-v3.pdf" mimetype="application" mime-subtype="pdf"/></supplementary-material></sec><sec sec-type="data-availability" id="s7"><title>Data availability</title><p>All data generated or analyzed during this study are included in the manuscript and supporting files.</p></sec><ack id="ack"><title>Acknowledgements</title><p>We thank Nancy Sanchez for assistance with cloning the S1221P BRCA2 mutation and Agata Smogorzewska for the HA-RAD51 and HA-RAD51 T131P constructs. We thank all members of the Jensen Lab for helpful comments and review of this article. Sudipta Lahiri thanks Rothenberg lab members, especially Dr. Carolus Fijen and Dr. Huijun Xue for help with smFRET experiments and data analysis. The graphical abstract and schematics were created with <ext-link ext-link-type="uri" xlink:href="https://biorender.com/">https://biorender.com/</ext-link> This research was supported by grants from the NIH (RO1 CA215990), Women’s Health Research at Yale, and The Gray Foundation to RBJ, and NIH grants R35 GM134947, AI153040, and CA247773 to ER Further support was provided by The V Foundation BRCA Research collaborative grant (to RBJ &amp; ER), Pfizer (ER), and funds from the Chavkin philanthropic contribution to the Perlmutter Cancer Center (ER), and a Lion Heart Pilot Grant to JJ-S.</p></ack><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abul-Husn</surname><given-names>NS</given-names></name><name><surname>Soper</surname><given-names>ER</given-names></name><name><surname>Odgis</surname><given-names>JA</given-names></name><name><surname>Cullina</surname><given-names>S</given-names></name><name><surname>Bobo</surname><given-names>D</given-names></name><name><surname>Moscati</surname><given-names>A</given-names></name><name><surname>Rodriguez</surname><given-names>JE</given-names></name><collab>CBIPM Genomics Team</collab><collab>Regeneron Genetics Center</collab><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Cho</surname><given-names>JH</given-names></name><name><surname>Belbin</surname><given-names>GM</given-names></name><name><surname>Suckiel</surname><given-names>SA</given-names></name><name><surname>Kenny</surname><given-names>EE</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Exome sequencing reveals a high prevalence of BRCA1 and BRCA2 founder variants in a diverse population-based Biobank</article-title><source>Genome Medicine</source><volume>12</volume><elocation-id>2</elocation-id><pub-id pub-id-type="doi">10.1186/s13073-019-0691-1</pub-id><pub-id pub-id-type="pmid">31892343</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Anand</surname><given-names>R</given-names></name><name><surname>Pinto</surname><given-names>C</given-names></name><name><surname>Cejka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Methods to study DNA end resection I: recombinant protein purification</article-title><source>Methods in Enzymology</source><volume>600</volume><fpage>25</fpage><lpage>66</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2017.11.008</pub-id><pub-id pub-id-type="pmid">29458761</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ban</surname><given-names>S</given-names></name><name><surname>Shinohara</surname><given-names>T</given-names></name><name><surname>Hirai</surname><given-names>Y</given-names></name><name><surname>Moritaku</surname><given-names>Y</given-names></name><name><surname>Cologne</surname><given-names>JB</given-names></name><name><surname>MacPhee</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Chromosomal instability in BRCA1- or BRCA2-defective human cancer cells detected by spontaneous micronucleus assay</article-title><source>Mutation Research</source><volume>474</volume><fpage>15</fpage><lpage>23</lpage><pub-id pub-id-type="doi">10.1016/s0027-5107(00)00152-4</pub-id><pub-id pub-id-type="pmid">11239959</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bertwistle</surname><given-names>D</given-names></name><name><surname>Swift</surname><given-names>S</given-names></name><name><surname>Marston</surname><given-names>NJ</given-names></name><name><surname>Jackson</surname><given-names>LE</given-names></name><name><surname>Crossland</surname><given-names>S</given-names></name><name><surname>Crompton</surname><given-names>MR</given-names></name><name><surname>Marshall</surname><given-names>CJ</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Nuclear location and cell cycle regulation of the BRCA2 protein</article-title><source>Cancer Research</source><volume>57</volume><fpage>5485</fpage><lpage>5488</lpage><pub-id pub-id-type="pmid">9407955</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biasini</surname><given-names>M</given-names></name><name><surname>Schmidt</surname><given-names>T</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Mariani</surname><given-names>V</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Haas</surname><given-names>J</given-names></name><name><surname>Johner</surname><given-names>N</given-names></name><name><surname>Schenk</surname><given-names>AD</given-names></name><name><surname>Philippsen</surname><given-names>A</given-names></name><name><surname>Schwede</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>OpenStructure: an integrated software framework for computational structural biology</article-title><source>Acta Crystallographica. Section D, Biological Crystallography</source><volume>69</volume><fpage>701</fpage><lpage>709</lpage><pub-id pub-id-type="doi">10.1107/S0907444913007051</pub-id><pub-id pub-id-type="pmid">23633579</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bignell</surname><given-names>G</given-names></name><name><surname>Micklem</surname><given-names>G</given-names></name><name><surname>Stratton</surname><given-names>MR</given-names></name><name><surname>Ashworth</surname><given-names>A</given-names></name><name><surname>Wooster</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>The BRC repeats are conserved in mammalian BRCA2 proteins</article-title><source>Human Molecular Genetics</source><volume>6</volume><fpage>53</fpage><lpage>58</lpage><pub-id pub-id-type="doi">10.1093/hmg/6.1.53</pub-id><pub-id pub-id-type="pmid">9002670</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>K.</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Alter</surname><given-names>BP</given-names></name><name><surname>Kuznetsov</surname><given-names>SG</given-names></name><name><surname>Stauffer</surname><given-names>S</given-names></name><name><surname>North</surname><given-names>SL</given-names></name><name><surname>Burkett</surname><given-names>S</given-names></name><name><surname>Brody</surname><given-names>LC</given-names></name><name><surname>Meyer</surname><given-names>S</given-names></name><name><surname>Byrd</surname><given-names>RA</given-names></name><name><surname>Sharan</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>A comprehensive functional characterization of BRCA2 variants associated with Fanconi anemia using mouse ES cell-based assay</article-title><source>Blood</source><volume>118</volume><fpage>2430</fpage><lpage>2442</lpage><pub-id pub-id-type="doi">10.1182/blood-2010-12-324541</pub-id><pub-id pub-id-type="pmid">21719596</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>K</given-names></name><name><surname>Das</surname><given-names>R</given-names></name><name><surname>Eggington</surname><given-names>JM</given-names></name><name><surname>Qiao</surname><given-names>H</given-names></name><name><surname>North</surname><given-names>SL</given-names></name><name><surname>Stauffer</surname><given-names>S</given-names></name><name><surname>Burkett</surname><given-names>SS</given-names></name><name><surname>Martin</surname><given-names>BK</given-names></name><name><surname>Southon</surname><given-names>E</given-names></name><name><surname>Sizemore</surname><given-names>SC</given-names></name><name><surname>Pruss</surname><given-names>D</given-names></name><name><surname>Bowles</surname><given-names>KR</given-names></name><name><surname>Roa</surname><given-names>BB</given-names></name><name><surname>Hunter</surname><given-names>N</given-names></name><name><surname>Tessarollo</surname><given-names>L</given-names></name><name><surname>Wenstrup</surname><given-names>RJ</given-names></name><name><surname>Byrd</surname><given-names>RA</given-names></name><name><surname>Sharan</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Functional evaluation of BRCA2 variants mapping to the PALB2-binding and C-terminal DNA-binding domains using a mouse ES cell-based assay</article-title><source>Human Molecular Genetics</source><volume>21</volume><fpage>3993</fpage><lpage>4006</lpage><pub-id pub-id-type="doi">10.1093/hmg/dds222</pub-id><pub-id pub-id-type="pmid">22678057</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biswas</surname><given-names>K</given-names></name><name><surname>Lipton</surname><given-names>GB</given-names></name><name><surname>Stauffer</surname><given-names>S</given-names></name><name><surname>Sullivan</surname><given-names>T</given-names></name><name><surname>Cleveland</surname><given-names>L</given-names></name><name><surname>Southon</surname><given-names>E</given-names></name><name><surname>Reid</surname><given-names>S</given-names></name><name><surname>Magidson</surname><given-names>V</given-names></name><name><surname>Iversen</surname><given-names>ES</given-names></name><name><surname>Sharan</surname><given-names>SK</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>A computational model for classification of BRCA2 variants using mouse embryonic stem cell-based functional assays</article-title><source>NPJ Genomic Medicine</source><volume>5</volume><elocation-id>52</elocation-id><pub-id pub-id-type="doi">10.1038/s41525-020-00158-5</pub-id><pub-id pub-id-type="pmid">33293522</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bugreev</surname><given-names>DV</given-names></name><name><surname>Mazin</surname><given-names>AV</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Ca2+ activates human homologous recombination protein Rad51 by modulating its ATPase activity</article-title><source>PNAS</source><volume>101</volume><fpage>9988</fpage><lpage>9993</lpage><pub-id pub-id-type="doi">10.1073/pnas.0402105101</pub-id><pub-id pub-id-type="pmid">15226506</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carpenter</surname><given-names>AE</given-names></name><name><surname>Jones</surname><given-names>TR</given-names></name><name><surname>Lamprecht</surname><given-names>MR</given-names></name><name><surname>Clarke</surname><given-names>C</given-names></name><name><surname>Kang</surname><given-names>IH</given-names></name><name><surname>Friman</surname><given-names>O</given-names></name><name><surname>Guertin</surname><given-names>DA</given-names></name><name><surname>Chang</surname><given-names>JH</given-names></name><name><surname>Lindquist</surname><given-names>RA</given-names></name><name><surname>Moffat</surname><given-names>J</given-names></name><name><surname>Golland</surname><given-names>P</given-names></name><name><surname>Sabatini</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CellProfiler: image analysis software for identifying and quantifying cell phenotypes</article-title><source>Genome Biology</source><volume>7</volume><elocation-id>R100</elocation-id><pub-id pub-id-type="doi">10.1186/gb-2006-7-10-r100</pub-id><pub-id pub-id-type="pmid">17076895</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreira</surname><given-names>Aura</given-names></name><name><surname>Hilario</surname><given-names>J</given-names></name><name><surname>Amitani</surname><given-names>I</given-names></name><name><surname>Baskin</surname><given-names>RJ</given-names></name><name><surname>Shivji</surname><given-names>MKK</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The BRC repeats of BRCA2 modulate the DNA-binding selectivity of Rad51</article-title><source>Cell</source><volume>136</volume><fpage>1032</fpage><lpage>1043</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.02.019</pub-id><pub-id pub-id-type="pmid">19303847</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carreira</surname><given-names>A</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Two classes of BRC repeats in BRCA2 promote Rad51 nucleoprotein filament function by distinct mechanisms</article-title><source>PNAS</source><volume>108</volume><fpage>10448</fpage><lpage>10453</lpage><pub-id pub-id-type="doi">10.1073/pnas.1106971108</pub-id><pub-id pub-id-type="pmid">21670257</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carvalho</surname><given-names>MA</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Monteiro</surname><given-names>ANA</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Functional assays for BRCA1 and BRCA2</article-title><source>The International Journal of Biochemistry &amp; Cell Biology</source><volume>39</volume><fpage>298</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.biocel.2006.08.002</pub-id><pub-id pub-id-type="pmid">16978908</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chatterjee</surname><given-names>G</given-names></name><name><surname>Jimenez-Sainz</surname><given-names>J</given-names></name><name><surname>Presti</surname><given-names>T</given-names></name><name><surname>Nguyen</surname><given-names>T</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Distinct binding of BRCA2 BRC repeats to Rad51 generates differential DNA damage sensitivity</article-title><source>Nucleic Acids Research</source><volume>44</volume><fpage>5256</fpage><lpage>5270</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw242</pub-id><pub-id pub-id-type="pmid">27084934</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Chen</surname><given-names>CF</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>J</given-names></name><name><surname>Sharp</surname><given-names>ZD</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>The BRC repeats in BRCA2 are critical for Rad51 binding and resistance to methyl methanesulfonate treatment</article-title><source>PNAS</source><volume>95</volume><fpage>5287</fpage><lpage>5292</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.9.5287</pub-id><pub-id pub-id-type="pmid">9560268</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>JJ</given-names></name><name><surname>Silver</surname><given-names>D</given-names></name><name><surname>Cantor</surname><given-names>S</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name><name><surname>Scully</surname><given-names>R</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Brca1, BRCA2, and Rad51 operate in a common DNA damage response pathway</article-title><source>Cancer Research</source><volume>59</volume><fpage>1752s</fpage><lpage>1756s</lpage><pub-id pub-id-type="pmid">10197592</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Consortium</surname><given-names>U</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Ongoing and future developments at the universal protein resource</article-title><source>Nucleic Acids Research</source><volume>39</volume><fpage>D214</fpage><lpage>D129</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq1020</pub-id><pub-id pub-id-type="pmid">21051339</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davies</surname><given-names>AA</given-names></name><name><surname>Masson</surname><given-names>JY</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Stasiak</surname><given-names>AZ</given-names></name><name><surname>Stasiak</surname><given-names>A</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name><name><surname>West</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Role of BRCA2 in control of the Rad51 recombination and DNA repair protein</article-title><source>Molecular Cell</source><volume>7</volume><fpage>273</fpage><lpage>282</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(01)00175-7</pub-id><pub-id pub-id-type="pmid">11239456</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esashi</surname><given-names>F</given-names></name><name><surname>Christ</surname><given-names>N</given-names></name><name><surname>Gannon</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hunt</surname><given-names>T</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name><name><surname>West</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>CDK-dependent phosphorylation of BRCA2 as a regulatory mechanism for recombinational repair</article-title><source>Nature</source><volume>434</volume><fpage>598</fpage><lpage>604</lpage><pub-id pub-id-type="doi">10.1038/nature03404</pub-id><pub-id pub-id-type="pmid">15800615</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esashi</surname><given-names>F</given-names></name><name><surname>Galkin</surname><given-names>VE</given-names></name><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Egelman</surname><given-names>EH</given-names></name><name><surname>West</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Stabilization of Rad51 nucleoprotein filaments by the C-terminal region of BRCA2</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>14</volume><fpage>468</fpage><lpage>474</lpage><pub-id pub-id-type="doi">10.1038/nsmb1245</pub-id><pub-id pub-id-type="pmid">17515904</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Farrugia</surname><given-names>DJ</given-names></name><name><surname>Agarwal</surname><given-names>MK</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Deffenbaugh</surname><given-names>AM</given-names></name><name><surname>Pruss</surname><given-names>D</given-names></name><name><surname>Frye</surname><given-names>C</given-names></name><name><surname>Wadum</surname><given-names>L</given-names></name><name><surname>Johnson</surname><given-names>K</given-names></name><name><surname>Mentlick</surname><given-names>J</given-names></name><name><surname>Tavtigian</surname><given-names>SV</given-names></name><name><surname>Goldgar</surname><given-names>DE</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Functional assays for classification of BRCA2 variants of uncertain significance</article-title><source>Cancer Research</source><volume>68</volume><fpage>3523</fpage><lpage>3531</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-1587</pub-id><pub-id pub-id-type="pmid">18451181</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidugli</surname><given-names>L</given-names></name><name><surname>Pankratz</surname><given-names>VS</given-names></name><name><surname>Singh</surname><given-names>N</given-names></name><name><surname>Thompson</surname><given-names>J</given-names></name><name><surname>Erding</surname><given-names>CA</given-names></name><name><surname>Engel</surname><given-names>C</given-names></name><name><surname>Schmutzler</surname><given-names>R</given-names></name><name><surname>Domchek</surname><given-names>S</given-names></name><name><surname>Nathanson</surname><given-names>K</given-names></name><name><surname>Radice</surname><given-names>P</given-names></name><name><surname>Singer</surname><given-names>C</given-names></name><name><surname>Tonin</surname><given-names>PN</given-names></name><name><surname>Lindor</surname><given-names>NM</given-names></name><name><surname>Goldgar</surname><given-names>DE</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A classification model for BRCA2 DNA binding domain missense variants based on homology-directed repair activity</article-title><source>Cancer Research</source><volume>73</volume><fpage>265</fpage><lpage>275</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-12-2081</pub-id><pub-id pub-id-type="pmid">23108138</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guidugli</surname><given-names>L</given-names></name><name><surname>Carreira</surname><given-names>A</given-names></name><name><surname>Caputo</surname><given-names>SM</given-names></name><name><surname>Ehlen</surname><given-names>A</given-names></name><name><surname>Galli</surname><given-names>A</given-names></name><name><surname>Monteiro</surname><given-names>ANA</given-names></name><name><surname>Neuhausen</surname><given-names>SL</given-names></name><name><surname>Hansen</surname><given-names>TVO</given-names></name><name><surname>Couch</surname><given-names>FJ</given-names></name><name><surname>Vreeswijk</surname><given-names>MPG</given-names></name><collab>ENIGMA consortium</collab></person-group><year iso-8601-date="2014">2014</year><article-title>Functional assays for analysis of variants of uncertain significance in BRCA2</article-title><source>Human Mutation</source><volume>35</volume><fpage>151</fpage><lpage>164</lpage><pub-id pub-id-type="doi">10.1002/humu.22478</pub-id><pub-id pub-id-type="pmid">24323938</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haaf</surname><given-names>T</given-names></name><name><surname>Golub</surname><given-names>EI</given-names></name><name><surname>Reddy</surname><given-names>G</given-names></name><name><surname>Radding</surname><given-names>CM</given-names></name><name><surname>Ward</surname><given-names>DC</given-names></name></person-group><year iso-8601-date="1995">1995</year><article-title>Nuclear foci of mammalian Rad51 recombination protein in somatic cells after DNA damage and its localization in synaptonemal complexes</article-title><source>PNAS</source><volume>92</volume><fpage>2298</fpage><lpage>2302</lpage><pub-id pub-id-type="doi">10.1073/pnas.92.6.2298</pub-id><pub-id pub-id-type="pmid">7892263</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="confproc"><person-group person-group-type="author"><name><surname>Hall</surname><given-names>TA</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>BioEdit: a user-friendly biological sequence alignment editor and analysis program for windows 95/98/NT</article-title><conf-name>In Nucleic acids symposium series 41</conf-name><fpage>95</fpage><lpage>98</lpage></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>X</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name><name><surname>Nakanishi</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A CRM1-mediated nuclear export signal governs cytoplasmic localization of BRCA2 and is essential for centrosomal localization of BRCA2</article-title><source>Oncogene</source><volume>27</volume><fpage>2969</fpage><lpage>2977</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1210968</pub-id><pub-id pub-id-type="pmid">18059333</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heddle</surname><given-names>JA</given-names></name><name><surname>Hite</surname><given-names>M</given-names></name><name><surname>Kirkhart</surname><given-names>B</given-names></name><name><surname>Mavournin</surname><given-names>K</given-names></name><name><surname>MacGregor</surname><given-names>JT</given-names></name><name><surname>Newell</surname><given-names>GW</given-names></name><name><surname>Salamone</surname><given-names>MF</given-names></name></person-group><year iso-8601-date="1983">1983</year><article-title>The induction of micronuclei as a measure of genotoxicity</article-title><source>Mutation Research/Reviews in Genetic Toxicology</source><volume>123</volume><fpage>61</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1016/0165-1110(83)90047-7</pub-id><pub-id pub-id-type="pmid">6888413</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hucl</surname><given-names>T</given-names></name><name><surname>Rago</surname><given-names>C</given-names></name><name><surname>Gallmeier</surname><given-names>E</given-names></name><name><surname>Brody</surname><given-names>JR</given-names></name><name><surname>Gorospe</surname><given-names>M</given-names></name><name><surname>Kern</surname><given-names>SE</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>A syngeneic variance library for functional annotation of human variation: application to BRCA2</article-title><source>Cancer Research</source><volume>68</volume><fpage>5023</fpage><lpage>5030</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-07-6189</pub-id><pub-id pub-id-type="pmid">18593900</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Islam</surname><given-names>MN</given-names></name><name><surname>Paquet</surname><given-names>N</given-names></name><name><surname>Fox</surname><given-names>D</given-names></name><name><surname>Dray</surname><given-names>E</given-names></name><name><surname>Zheng</surname><given-names>XF</given-names></name><name><surname>Klein</surname><given-names>H</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>A variant of the breast cancer type 2 susceptibility protein (BRC) repeat is essential for the RECQL5 helicase to interact with Rad51 recombinase for genome stabilization</article-title><source>The Journal of Biological Chemistry</source><volume>287</volume><fpage>23808</fpage><lpage>23818</lpage><pub-id pub-id-type="doi">10.1074/jbc.M112.375014</pub-id><pub-id pub-id-type="pmid">22645136</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>RB</given-names></name><name><surname>Carreira</surname><given-names>A</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Purified human BRCA2 stimulates RAD51-mediated recombination</article-title><source>Nature</source><volume>467</volume><fpage>678</fpage><lpage>683</lpage><pub-id pub-id-type="doi">10.1038/nature09399</pub-id><pub-id pub-id-type="pmid">20729832</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jensen</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Purification of recombinant 2XMBP tagged human proteins from human cells</article-title><source>Methods in Molecular Biology</source><volume>1176</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="doi">10.1007/978-1-4939-0992-6_17</pub-id><pub-id pub-id-type="pmid">25030930</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeyasekharan</surname><given-names>AD</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Hattori</surname><given-names>H</given-names></name><name><surname>Pisupati</surname><given-names>V</given-names></name><name><surname>Jonsdottir</surname><given-names>AB</given-names></name><name><surname>Rajendra</surname><given-names>E</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Sundaramoorthy</surname><given-names>E</given-names></name><name><surname>Schlachter</surname><given-names>S</given-names></name><name><surname>Kaminski</surname><given-names>CF</given-names></name><name><surname>Ofir-Rosenfeld</surname><given-names>Y</given-names></name><name><surname>Sato</surname><given-names>K</given-names></name><name><surname>Savill</surname><given-names>J</given-names></name><name><surname>Ayoub</surname><given-names>N</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>A cancer-associated BRCA2 mutation reveals masked nuclear export signals controlling localization</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>20</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="doi">10.1038/nsmb.2666</pub-id><pub-id pub-id-type="pmid">24013206</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Sainz</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Imprecise medicine: BRCA2 variants of uncertain significance (VUS), the challenges and benefits to integrate a functional assay workflow with clinical decision rules</article-title><source>Genes</source><volume>12</volume><elocation-id>780</elocation-id><pub-id pub-id-type="doi">10.3390/genes12050780</pub-id><pub-id pub-id-type="pmid">34065235</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jimenez-Sainz</surname><given-names>J</given-names></name><name><surname>Krysztofiak</surname><given-names>A</given-names></name><name><surname>Garbarino</surname><given-names>J</given-names></name><name><surname>Rogers</surname><given-names>F</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>The pathogenic R3052W BRCA2 variant disrupts homology-directed repair by failing to localize to the nucleus</article-title><source>Frontiers in Genetics</source><volume>13</volume><elocation-id>884210</elocation-id><pub-id pub-id-type="doi">10.3389/fgene.2022.884210</pub-id><pub-id pub-id-type="pmid">35711920</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kojic</surname><given-names>M</given-names></name><name><surname>Kostrub</surname><given-names>CF</given-names></name><name><surname>Buchman</surname><given-names>AR</given-names></name><name><surname>Holloman</surname><given-names>WK</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Brca2 homolog required for proficiency in DNA repair, recombination, and genome stability in <italic>Ustilago maydis</italic></article-title><source>Molecular Cell</source><volume>10</volume><fpage>683</fpage><lpage>691</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(02)00632-9</pub-id><pub-id pub-id-type="pmid">12408834</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lahiri</surname><given-names>S</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Dna strand exchange to monitor human RAD51-mediated strand invasion and pairing</article-title><source>Methods in Molecular Biology</source><volume>2153</volume><fpage>101</fpage><lpage>113</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-0644-5_8</pub-id><pub-id pub-id-type="pmid">32840775</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Larkin</surname><given-names>MA</given-names></name><name><surname>Blackshields</surname><given-names>G</given-names></name><name><surname>Brown</surname><given-names>NP</given-names></name><name><surname>Chenna</surname><given-names>R</given-names></name><name><surname>McGettigan</surname><given-names>PA</given-names></name><name><surname>McWilliam</surname><given-names>H</given-names></name><name><surname>Valentin</surname><given-names>F</given-names></name><name><surname>Wallace</surname><given-names>IM</given-names></name><name><surname>Wilm</surname><given-names>A</given-names></name><name><surname>Lopez</surname><given-names>R</given-names></name><name><surname>Thompson</surname><given-names>JD</given-names></name><name><surname>Gibson</surname><given-names>TJ</given-names></name><name><surname>Higgins</surname><given-names>DG</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Clustal W and clustal X version 2.0</article-title><source>Bioinformatics</source><volume>23</volume><fpage>2947</fpage><lpage>2948</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btm404</pub-id><pub-id pub-id-type="pmid">17846036</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Shorthouse</surname><given-names>D</given-names></name><name><surname>Mahen</surname><given-names>R</given-names></name><name><surname>Hall</surname><given-names>BA</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cancer-Causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance</article-title><source>Nucleic Acids Research</source><volume>49</volume><fpage>5588</fpage><lpage>5604</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab308</pub-id><pub-id pub-id-type="pmid">33978741</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Doty</surname><given-names>T</given-names></name><name><surname>Gibson</surname><given-names>B</given-names></name><name><surname>Heyer</surname><given-names>WD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Human BRCA2 protein promotes Rad51 filament formation on RPA-covered single-stranded DNA</article-title><source>Nature Structural &amp; Molecular Biology</source><volume>17</volume><fpage>1260</fpage><lpage>1262</lpage><pub-id pub-id-type="doi">10.1038/nsmb.1904</pub-id><pub-id pub-id-type="pmid">20729859</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lo</surname><given-names>T</given-names></name><name><surname>Pellegrini</surname><given-names>L</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Sequence fingerprints in BRCA2 and Rad51: implications for DNA repair and cancer</article-title><source>DNA Repair</source><volume>2</volume><fpage>1015</fpage><lpage>1028</lpage><pub-id pub-id-type="doi">10.1016/s1568-7864(03)00097-1</pub-id><pub-id pub-id-type="pmid">12967658</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Magwood</surname><given-names>AC</given-names></name><name><surname>Malysewich</surname><given-names>MJ</given-names></name><name><surname>Cealic</surname><given-names>I</given-names></name><name><surname>Mundia</surname><given-names>MM</given-names></name><name><surname>Knapp</surname><given-names>J</given-names></name><name><surname>Baker</surname><given-names>MD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Endogenous levels of Rad51 and BRCA2 are required for homologous recombination and regulated by homeostatic re-balancing</article-title><source>DNA Repair</source><volume>12</volume><fpage>1122</fpage><lpage>1133</lpage><pub-id pub-id-type="doi">10.1016/j.dnarep.2013.10.006</pub-id><pub-id pub-id-type="pmid">24210700</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Marsden</surname><given-names>CG</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name><name><surname>Zagelbaum</surname><given-names>J</given-names></name><name><surname>Rothenberg</surname><given-names>E</given-names></name><name><surname>Morrical</surname><given-names>SW</given-names></name><name><surname>Wallace</surname><given-names>SS</given-names></name><name><surname>Sweasy</surname><given-names>JB</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The tumor-associated variant Rad51 G151D induces a hyper-recombination phenotype</article-title><source>PLOS Genetics</source><volume>12</volume><elocation-id>e1006208</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pgen.1006208</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martin</surname><given-names>JS</given-names></name><name><surname>Winkelmann</surname><given-names>N</given-names></name><name><surname>Petalcorin</surname><given-names>MIR</given-names></name><name><surname>McIlwraith</surname><given-names>MJ</given-names></name><name><surname>Boulton</surname><given-names>SJ</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>RAD-51-dependent and -independent roles of a <italic>Caenorhabditis elegans</italic> BRCA2-related protein during DNA double-strand break repair</article-title><source>Molecular and Cellular Biology</source><volume>25</volume><fpage>3127</fpage><lpage>3139</lpage><pub-id pub-id-type="doi">10.1128/MCB.25.8.3127-3139.2005</pub-id><pub-id pub-id-type="pmid">15798199</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maya-Mendoza</surname><given-names>A</given-names></name><name><surname>Moudry</surname><given-names>P</given-names></name><name><surname>Merchut-Maya</surname><given-names>JM</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Strauss</surname><given-names>R</given-names></name><name><surname>Bartek</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>High speed of fork progression induces DNA replication stress and genomic instability</article-title><source>Nature</source><volume>559</volume><fpage>279</fpage><lpage>284</lpage><pub-id pub-id-type="doi">10.1038/s41586-018-0261-5</pub-id><pub-id pub-id-type="pmid">29950726</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McAllister</surname><given-names>KA</given-names></name><name><surname>Haugen-Strano</surname><given-names>A</given-names></name><name><surname>Hagevik</surname><given-names>S</given-names></name><name><surname>Brownlee</surname><given-names>HA</given-names></name><name><surname>Collins</surname><given-names>NK</given-names></name><name><surname>Futreal</surname><given-names>PA</given-names></name><name><surname>Bennett</surname><given-names>LM</given-names></name><name><surname>Wiseman</surname><given-names>RW</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Characterization of the rat and mouse homologues of the BRCA2 breast cancer susceptibility gene</article-title><source>Cancer Research</source><volume>57</volume><fpage>3121</fpage><lpage>3125</lpage><pub-id pub-id-type="pmid">9242436</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mizuta</surname><given-names>R</given-names></name><name><surname>LaSalle</surname><given-names>JM</given-names></name><name><surname>Cheng</surname><given-names>HL</given-names></name><name><surname>Shinohara</surname><given-names>A</given-names></name><name><surname>Ogawa</surname><given-names>H</given-names></name><name><surname>Copeland</surname><given-names>N</given-names></name><name><surname>Jenkins</surname><given-names>NA</given-names></name><name><surname>Lalande</surname><given-names>M</given-names></name><name><surname>Alt</surname><given-names>FW</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Rab22 and RAB163/mouse BRCA2: proteins that specifically interact with the Rad51 protein</article-title><source>PNAS</source><volume>94</volume><fpage>6927</fpage><lpage>6932</lpage><pub-id pub-id-type="doi">10.1073/pnas.94.13.6927</pub-id><pub-id pub-id-type="pmid">9192668</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moore</surname><given-names>G</given-names></name><name><surname>Jimenez Sainz</surname><given-names>J</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name></person-group><year iso-8601-date="2022">2022</year><article-title>Dna fiber combing protocol using in-house reagents and coverslips to analyze replication fork dynamics in mammalian cells</article-title><source>STAR Protocols</source><volume>3</volume><elocation-id>101371</elocation-id><pub-id pub-id-type="doi">10.1016/j.xpro.2022.101371</pub-id><pub-id pub-id-type="pmid">35573479</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moynahan</surname><given-names>ME</given-names></name><name><surname>Pierce</surname><given-names>AJ</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Brca2 is required for homology-directed repair of chromosomal breaks</article-title><source>Molecular Cell</source><volume>7</volume><fpage>263</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(01)00174-5</pub-id><pub-id pub-id-type="pmid">11239455</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Olopade</surname><given-names>OI</given-names></name><name><surname>Fackenthal</surname><given-names>JD</given-names></name><name><surname>Dunston</surname><given-names>G</given-names></name><name><surname>Tainsky</surname><given-names>MA</given-names></name><name><surname>Collins</surname><given-names>F</given-names></name><name><surname>Whitfield-Broome</surname><given-names>C</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Breast cancer genetics in African Americans</article-title><source>Cancer</source><volume>97</volume><fpage>236</fpage><lpage>245</lpage><pub-id pub-id-type="doi">10.1002/cncr.11019</pub-id><pub-id pub-id-type="pmid">12491487</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Orthwein</surname><given-names>A</given-names></name><name><surname>Noordermeer</surname><given-names>SM</given-names></name><name><surname>Wilson</surname><given-names>MD</given-names></name><name><surname>Landry</surname><given-names>S</given-names></name><name><surname>Enchev</surname><given-names>RI</given-names></name><name><surname>Sherker</surname><given-names>A</given-names></name><name><surname>Munro</surname><given-names>M</given-names></name><name><surname>Pinder</surname><given-names>J</given-names></name><name><surname>Salsman</surname><given-names>J</given-names></name><name><surname>Dellaire</surname><given-names>G</given-names></name><name><surname>Xia</surname><given-names>B</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Durocher</surname><given-names>D</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A mechanism for the suppression of homologous recombination in G1 cells</article-title><source>Nature</source><volume>528</volume><fpage>422</fpage><lpage>426</lpage><pub-id pub-id-type="doi">10.1038/nature16142</pub-id><pub-id pub-id-type="pmid">26649820</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>KJ</given-names></name><name><surname>Yu</surname><given-names>VP</given-names></name><name><surname>Lee</surname><given-names>H</given-names></name><name><surname>Corcoran</surname><given-names>A</given-names></name><name><surname>Thistlethwaite</surname><given-names>FC</given-names></name><name><surname>Evans</surname><given-names>MJ</given-names></name><name><surname>Colledge</surname><given-names>WH</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Ponder</surname><given-names>BA</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Involvement of BRCA2 in DNA repair</article-title><source>Molecular Cell</source><volume>1</volume><fpage>347</fpage><lpage>357</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(00)80035-0</pub-id><pub-id pub-id-type="pmid">9660919</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pellegrini</surname><given-names>L</given-names></name><name><surname>Yu</surname><given-names>DS</given-names></name><name><surname>Lo</surname><given-names>T</given-names></name><name><surname>Anand</surname><given-names>S</given-names></name><name><surname>Lee</surname><given-names>M</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Insights into DNA recombination from the structure of a RAD51-BRCA2 complex</article-title><source>Nature</source><volume>420</volume><fpage>287</fpage><lpage>293</lpage><pub-id pub-id-type="doi">10.1038/nature01230</pub-id><pub-id pub-id-type="pmid">12442171</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pinder</surname><given-names>J</given-names></name><name><surname>Salsman</surname><given-names>J</given-names></name><name><surname>Dellaire</surname><given-names>G</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Nuclear domain “ knock-in ” screen for the evaluation and identification of small molecule enhancers of CRISPR-based genome editing</article-title><source>Nucleic Acids Research</source><volume>43</volume><fpage>9379</fpage><lpage>9392</lpage><pub-id pub-id-type="doi">10.1093/nar/gkv993</pub-id><pub-id pub-id-type="pmid">26429972</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Piwko</surname><given-names>W</given-names></name><name><surname>Mlejnkova</surname><given-names>LJ</given-names></name><name><surname>Mutreja</surname><given-names>K</given-names></name><name><surname>Ranjha</surname><given-names>L</given-names></name><name><surname>Stafa</surname><given-names>D</given-names></name><name><surname>Smirnov</surname><given-names>A</given-names></name><name><surname>Brodersen</surname><given-names>MM</given-names></name><name><surname>Zellweger</surname><given-names>R</given-names></name><name><surname>Sturzenegger</surname><given-names>A</given-names></name><name><surname>Janscak</surname><given-names>P</given-names></name><name><surname>Lopes</surname><given-names>M</given-names></name><name><surname>Peter</surname><given-names>M</given-names></name><name><surname>Cejka</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>The MMS22L-TONSL heterodimer directly promotes Rad51-dependent recombination upon replication stress</article-title><source>The EMBO Journal</source><volume>35</volume><fpage>2584</fpage><lpage>2601</lpage><pub-id pub-id-type="doi">10.15252/embj.201593132</pub-id><pub-id pub-id-type="pmid">27797818</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothenberg</surname><given-names>E</given-names></name><name><surname>Ha</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Single-Molecule FRET analysis of helicase functions</article-title><source>Methods in Molecular Biology</source><volume>587</volume><fpage>29</fpage><lpage>43</lpage><pub-id pub-id-type="doi">10.1007/978-1-60327-355-8_3</pub-id><pub-id pub-id-type="pmid">20225140</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rothkamm</surname><given-names>K</given-names></name><name><surname>Barnard</surname><given-names>S</given-names></name><name><surname>Moquet</surname><given-names>J</given-names></name><name><surname>Ellender</surname><given-names>M</given-names></name><name><surname>Rana</surname><given-names>Z</given-names></name><name><surname>Burdak-Rothkamm</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Dna damage foci: meaning and significance</article-title><source>Environmental and Molecular Mutagenesis</source><volume>56</volume><fpage>491</fpage><lpage>504</lpage><pub-id pub-id-type="doi">10.1002/em.21944</pub-id><pub-id pub-id-type="pmid">25773265</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>San Filippo</surname><given-names>J</given-names></name><name><surname>Chi</surname><given-names>P</given-names></name><name><surname>Sehorn</surname><given-names>MG</given-names></name><name><surname>Etchin</surname><given-names>J</given-names></name><name><surname>Krejci</surname><given-names>L</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Recombination mediator and Rad51 targeting activities of a human BRCA2 polypeptide</article-title><source>The Journal of Biological Chemistry</source><volume>281</volume><fpage>11649</fpage><lpage>11657</lpage><pub-id pub-id-type="doi">10.1074/jbc.M601249200</pub-id><pub-id pub-id-type="pmid">16513631</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schlacher</surname><given-names>K</given-names></name><name><surname>Christ</surname><given-names>N</given-names></name><name><surname>Siaud</surname><given-names>N</given-names></name><name><surname>Egashira</surname><given-names>A</given-names></name><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Jasin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Double-Strand break repair-independent role for BRCA2 in blocking stalled replication fork degradation by Mre11</article-title><source>Cell</source><volume>145</volume><fpage>529</fpage><lpage>542</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2011.03.041</pub-id><pub-id pub-id-type="pmid">21565612</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schneider</surname><given-names>CA</given-names></name><name><surname>Rasband</surname><given-names>WS</given-names></name><name><surname>Eliceiri</surname><given-names>KW</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>Nih image to imagej: 25 years of image analysis</article-title><source>Nature Methods</source><volume>9</volume><fpage>671</fpage><lpage>675</lpage><pub-id pub-id-type="doi">10.1038/nmeth.2089</pub-id><pub-id pub-id-type="pmid">22930834</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scully</surname><given-names>R</given-names></name><name><surname>Livingston</surname><given-names>DM</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>In search of the tumour-suppressor functions of BRCA1 and BRCA2</article-title><source>Nature</source><volume>408</volume><fpage>429</fpage><lpage>432</lpage><pub-id pub-id-type="doi">10.1038/35044000</pub-id><pub-id pub-id-type="pmid">11100717</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sharan</surname><given-names>SK</given-names></name><name><surname>Morimatsu</surname><given-names>M</given-names></name><name><surname>Albrecht</surname><given-names>U</given-names></name><name><surname>Lim</surname><given-names>DS</given-names></name><name><surname>Regel</surname><given-names>E</given-names></name><name><surname>Dinh</surname><given-names>C</given-names></name><name><surname>Sands</surname><given-names>A</given-names></name><name><surname>Eichele</surname><given-names>G</given-names></name><name><surname>Hasty</surname><given-names>P</given-names></name><name><surname>Bradley</surname><given-names>A</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Embryonic lethality and radiation hypersensitivity mediated by RAD51 in mice lacking BRCA2</article-title><source>Nature</source><volume>386</volume><fpage>804</fpage><lpage>810</lpage><pub-id pub-id-type="doi">10.1038/386804a0</pub-id><pub-id pub-id-type="pmid">9126738</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Spain</surname><given-names>BH</given-names></name><name><surname>Larson</surname><given-names>CJ</given-names></name><name><surname>Shihabuddin</surname><given-names>LS</given-names></name><name><surname>Gage</surname><given-names>FH</given-names></name><name><surname>Verma</surname><given-names>IM</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Truncated BRCA2 is cytoplasmic: implications for cancer-linked mutations</article-title><source>PNAS</source><volume>96</volume><fpage>13920</fpage><lpage>13925</lpage><pub-id pub-id-type="doi">10.1073/pnas.96.24.13920</pub-id><pub-id pub-id-type="pmid">10570174</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Tauriello</surname><given-names>G</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Biasini</surname><given-names>M</given-names></name><name><surname>Johner</surname><given-names>N</given-names></name><name><surname>Schwede</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>ProMod3-A versatile homology modelling toolbox</article-title><source>PLOS Computational Biology</source><volume>17</volume><elocation-id>e1008667</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pcbi.1008667</pub-id><pub-id pub-id-type="pmid">33507980</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanyam</surname><given-names>S</given-names></name><name><surname>Kinz-Thompson</surname><given-names>CD</given-names></name><name><surname>Gonzalez</surname><given-names>RL</given-names></name><name><surname>Spies</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Observation and analysis of Rad51 nucleation dynamics at single-monomer resolution</article-title><source>Methods in Enzymology</source><volume>600</volume><fpage>201</fpage><lpage>232</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2017.12.008</pub-id><pub-id pub-id-type="pmid">29458759</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Subramanyam</surname><given-names>S</given-names></name><name><surname>Spies</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Expression, purification, and biochemical evaluation of human Rad51 protein</article-title><source>Methods in Enzymology</source><volume>600</volume><fpage>157</fpage><lpage>178</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2017.11.011</pub-id><pub-id pub-id-type="pmid">29458757</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tal</surname><given-names>A</given-names></name><name><surname>Arbel-Goren</surname><given-names>R</given-names></name><name><surname>Stavans</surname><given-names>J</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Cancer-Associated mutations in BRC domains of BRCA2 affect homologous recombination induced by Rad51</article-title><source>Journal of Molecular Biology</source><volume>393</volume><fpage>1007</fpage><lpage>1012</lpage><pub-id pub-id-type="doi">10.1016/j.jmb.2009.09.011</pub-id><pub-id pub-id-type="pmid">19747923</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thorslund</surname><given-names>T</given-names></name><name><surname>Esashi</surname><given-names>F</given-names></name><name><surname>West</surname><given-names>SC</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>Interactions between human BRCA2 protein and the meiosis-specific recombinase Dmc1</article-title><source>The EMBO Journal</source><volume>26</volume><fpage>2915</fpage><lpage>2922</lpage><pub-id pub-id-type="doi">10.1038/sj.emboj.7601739</pub-id><pub-id pub-id-type="pmid">17541404</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Cancer susceptibility and the functions of BRCA1 and BRCA2</article-title><source>Cell</source><volume>108</volume><fpage>171</fpage><lpage>182</lpage><pub-id pub-id-type="doi">10.1016/s0092-8674(02)00615-3</pub-id><pub-id pub-id-type="pmid">11832208</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>AT</given-names></name><name><surname>Kim</surname><given-names>T</given-names></name><name><surname>Wagner</surname><given-names>JE</given-names></name><name><surname>Conti</surname><given-names>BA</given-names></name><name><surname>Lach</surname><given-names>FP</given-names></name><name><surname>Huang</surname><given-names>AL</given-names></name><name><surname>Molina</surname><given-names>H</given-names></name><name><surname>Sanborn</surname><given-names>EM</given-names></name><name><surname>Zierhut</surname><given-names>H</given-names></name><name><surname>Cornes</surname><given-names>BK</given-names></name><name><surname>Abhyankar</surname><given-names>A</given-names></name><name><surname>Sougnez</surname><given-names>C</given-names></name><name><surname>Gabriel</surname><given-names>SB</given-names></name><name><surname>Auerbach</surname><given-names>AD</given-names></name><name><surname>Kowalczykowski</surname><given-names>SC</given-names></name><name><surname>Smogorzewska</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>A dominant mutation in human Rad51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination</article-title><source>Molecular Cell</source><volume>59</volume><fpage>478</fpage><lpage>490</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2015.07.009</pub-id><pub-id pub-id-type="pmid">26253028</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>A</given-names></name><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Tauriello</surname><given-names>G</given-names></name><name><surname>Gumienny</surname><given-names>R</given-names></name><name><surname>Heer</surname><given-names>FT</given-names></name><name><surname>de Beer</surname><given-names>TAP</given-names></name><name><surname>Rempfer</surname><given-names>C</given-names></name><name><surname>Bordoli</surname><given-names>L</given-names></name><name><surname>Lepore</surname><given-names>R</given-names></name><name><surname>Schwede</surname><given-names>T</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>SWISS-MODEL: homology modelling of protein structures and complexes</article-title><source>Nucleic Acids Research</source><volume>46</volume><fpage>W296</fpage><lpage>W303</lpage><pub-id pub-id-type="doi">10.1093/nar/gky427</pub-id><pub-id pub-id-type="pmid">29788355</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wong</surname><given-names>AK</given-names></name><name><surname>Pero</surname><given-names>R</given-names></name><name><surname>Ormonde</surname><given-names>PA</given-names></name><name><surname>Tavtigian</surname><given-names>SV</given-names></name><name><surname>Bartel</surname><given-names>PL</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Rad51 interacts with the evolutionarily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2</article-title><source>The Journal of Biological Chemistry</source><volume>272</volume><fpage>31941</fpage><lpage>31944</lpage><pub-id pub-id-type="doi">10.1074/jbc.272.51.31941</pub-id><pub-id pub-id-type="pmid">9405383</pub-id></element-citation></ref><ref id="bib73"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>H</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Miller</surname><given-names>J</given-names></name><name><surname>Kinnucan</surname><given-names>E</given-names></name><name><surname>Sun</surname><given-names>Y</given-names></name><name><surname>Thoma</surname><given-names>NH</given-names></name><name><surname>Zheng</surname><given-names>N</given-names></name><name><surname>Chen</surname><given-names>PL</given-names></name><name><surname>Lee</surname><given-names>WH</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Brca2 function in DNA binding and recombination from a BRCA2-DSS1-ssdna structure</article-title><source>Science</source><volume>297</volume><fpage>1837</fpage><lpage>1848</lpage><pub-id pub-id-type="doi">10.1126/science.297.5588.1837</pub-id><pub-id pub-id-type="pmid">12228710</pub-id></element-citation></ref><ref id="bib74"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yano</surname><given-names>K</given-names></name><name><surname>Morotomi</surname><given-names>K</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Matsuo</surname><given-names>F</given-names></name><name><surname>Miki</surname><given-names>Y</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Nuclear localization signals of the BRCA2 protein</article-title><source>Biochemical and Biophysical Research Communications</source><volume>270</volume><fpage>171</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1006/bbrc.2000.2392</pub-id><pub-id pub-id-type="pmid">10733923</pub-id></element-citation></ref><ref id="bib75"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>DS</given-names></name><name><surname>Sonoda</surname><given-names>E</given-names></name><name><surname>Takeda</surname><given-names>S</given-names></name><name><surname>Huang</surname><given-names>CLH</given-names></name><name><surname>Pellegrini</surname><given-names>L</given-names></name><name><surname>Blundell</surname><given-names>TL</given-names></name><name><surname>Venkitaraman</surname><given-names>AR</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Dynamic control of Rad51 recombinase by self-association and interaction with BRCA2</article-title><source>Molecular Cell</source><volume>12</volume><fpage>1029</fpage><lpage>1041</lpage><pub-id pub-id-type="doi">10.1016/s1097-2765(03)00394-0</pub-id><pub-id pub-id-type="pmid">14580352</pub-id></element-citation></ref><ref id="bib76"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zadorozhny</surname><given-names>K</given-names></name><name><surname>Sannino</surname><given-names>V</given-names></name><name><surname>Beláň</surname><given-names>O</given-names></name><name><surname>Mlčoušková</surname><given-names>J</given-names></name><name><surname>Špírek</surname><given-names>M</given-names></name><name><surname>Costanzo</surname><given-names>V</given-names></name><name><surname>Krejčí</surname><given-names>L</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Fanconi-anemia-associated mutations destabilize Rad51 filaments and impair replication fork protection</article-title><source>Cell Reports</source><volume>21</volume><fpage>333</fpage><lpage>340</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2017.09.062</pub-id><pub-id pub-id-type="pmid">29020621</pub-id></element-citation></ref><ref id="bib77"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Steinfeld</surname><given-names>JB</given-names></name><name><surname>Liang</surname><given-names>F</given-names></name><name><surname>Chen</surname><given-names>X</given-names></name><name><surname>Maranon</surname><given-names>DG</given-names></name><name><surname>Jian Ma</surname><given-names>C</given-names></name><name><surname>Kwon</surname><given-names>Y</given-names></name><name><surname>Rao</surname><given-names>T</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Sheng</surname><given-names>C</given-names></name><name><surname>Song</surname><given-names>X</given-names></name><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Jimenez-Sainz</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Jensen</surname><given-names>RB</given-names></name><name><surname>Xiong</surname><given-names>Y</given-names></name><name><surname>Kupfer</surname><given-names>GM</given-names></name><name><surname>Wiese</surname><given-names>C</given-names></name><name><surname>Greene</surname><given-names>EC</given-names></name><name><surname>Sung</surname><given-names>P</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Brca1-Bard1 promotes RAD51-mediated homologous DNA pairing</article-title><source>Nature</source><volume>550</volume><fpage>360</fpage><lpage>365</lpage><pub-id pub-id-type="doi">10.1038/nature24060</pub-id><pub-id pub-id-type="pmid">28976962</pub-id></element-citation></ref></ref-list><app-group><app id="appendix-1"><title>Appendix 1</title><table-wrap id="app1keyresource" position="anchor"><label>Appendix 1—key resources table</label><table frame="hsides" rules="groups"><thead><tr><th align="left" valign="bottom">Reagent type (species) or resource</th><th align="left" valign="bottom">Designation</th><th align="left" valign="bottom">Source or reference</th><th align="left" valign="bottom">Identifiers</th><th align="left" valign="bottom">Additional information</th></tr></thead><tbody><tr><td align="left" valign="bottom">Gene (<italic>Homo sapiens, Drosophila melanogaster, Mus musculus Felis catus, Rattus norvegicus</italic>,<break/><italic>Strongylocentrotus purpuratus,</italic><break/><italic>Monodelphis domestica,</italic><break/><italic>Canis lupus familiaris,</italic><break/><italic>Xenopus tropicalis</italic>)</td><td align="left" valign="bottom">BRCA2</td><td align="left" valign="bottom">Uniprot</td><td align="left" valign="bottom"><bold>P51587</bold> <italic>Homo sapiens (Human</italic>); <break/>Q<bold>9W157</bold> <italic>Drosophila melanogaster (Fruit fly);</italic> <break/><bold>P97929</bold><italic>Mus musculus (Mouse);</italic> <break/><bold>Q864S8</bold><italic>Felis catus (Cat);</italic> <break/><bold>O35923</bold><italic>Rattus norvegicus (Rat);</italic> <break/><bold>A5A3F7</bold> <italic>Strongylocentrotus purpuratus (Purple sea urchin);</italic> <break/><bold>A4ZZ89</bold><italic>Monodelphis domestica <break/>(Gray short-tailed opossum);</italic> <break/><bold>Q8MKI9</bold><italic>Canis lupus familiaris <break/>(Dog) (Canis familiaris);</italic> <break/><bold>A4ZZ90</bold><italic>Xenopus tropicalis (Western <break/>clawed frog) (Silurana tropicalis</italic>).</td><td align="left" valign="bottom">Alignment <xref ref-type="fig" rid="fig1">Figure 1</xref></td></tr><tr><td align="left" valign="bottom">Strain, strain <break/>background <break/>(<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Stellar Competent Cells</td><td align="left" valign="bottom">Takara-Clontech</td><td align="left" valign="bottom">Cat# 636766</td><td align="left" valign="bottom">Competent cells</td></tr><tr><td align="left" valign="bottom">Strain, strain <break/>background <break/>(<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom">Rosetta(DE3)pLysS Competent Cells</td><td align="left" valign="bottom">Sigma-Aldrich</td><td align="left" valign="bottom">Cat# 70956</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Strain, strain <break/>background <break/>(<italic>Escherichia coli</italic>)</td><td align="left" valign="bottom"><italic>E. coli</italic> Acella(DE3)/pCH1–RAD51o</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib66">Subramanyam and Spies, 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">DLD1</td><td align="left" valign="bottom">Horizon Discovery <xref ref-type="bibr" rid="bib29">Hucl et al., 2008</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">DLD1 BRCA2 -/-</td><td align="left" valign="bottom">Horizon Discovery <xref ref-type="bibr" rid="bib29">Hucl et al., 2008</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Cell line <break/>(<italic>Homo-sapiens</italic>)</td><td align="left" valign="bottom">HEK2093T</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pBluescript BRCA2 (1–5286 bp)</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pUC57 BRCA2 (2141–9117 bp) Genescript</td><td align="left" valign="bottom">Synthetized by<break/>Genescript</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pX330-LMNA-gRNA1</td><td align="left" valign="bottom">addgene</td><td align="char" char="." valign="bottom">122507</td><td align="left" valign="bottom">sgRNA plasmid targeting Lamin A</td></tr><tr><td align="left" valign="bottom">Recombinant DNA reagent</td><td align="left" valign="bottom">pCR2.1 Clover-LMNA Donor</td><td align="left" valign="bottom">Addgene</td><td align="char" char="." valign="bottom">122507</td><td align="left" valign="bottom">Donor</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="hyphen" valign="bottom">2XMBP-BRC2</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">YLTDENEVGFRGFYSAHGTKLNV<break/>STEALQKAVKLFSDIENISE<break/>ETSAEVHPISL*</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="hyphen" valign="bottom">2XMBP-BRC2-S1221P</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">YLTDENEVGFRGFYPAHGTKLN<break/>VSTEALQKAVKLFSDIENISE<break/>ETSAEVHPISL*</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="hyphen" valign="bottom">2XMBP-BRC7</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">GKLHKSVSSANTCGIFSTASGKS<break/>VQVSDASLQNARQVFSEIEDSTKQ*</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="hyphen" valign="bottom">2XMBP-BRC7-T1980I</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom">GKLHKSVSSANTCGIFSIASGKSV<break/>QVSDASLQNARQVFSEIEDSTKQ*</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="." valign="bottom">2XMBP BRCA2 WT</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="." valign="bottom">2XMBP BRCA2 S1221P</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="." valign="bottom">2XMBP BRCA2 T1346I</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Transfected construct (<italic>Homo-sapiens</italic>)</td><td align="char" char="." valign="bottom">2XMBP BRCA2 T1980I</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">RPA</td><td align="left" valign="bottom">This paper, <xref ref-type="bibr" rid="bib2">Anand et al., 2018</xref>;</td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">RAD51</td><td align="left" valign="bottom">This paper, <break/><xref ref-type="bibr" rid="bib66">Subramanyam and Spies, 2018</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">BRC2 peptide</td><td align="left" valign="bottom">Pierce, This paper</td><td align="left" valign="bottom">NEVGFRGFYSAHGTKLN<break/>VSTEALQKAVKLFSDIEN</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">BRC2-S1221P <break/>peptide</td><td align="left" valign="bottom">Pierce, This paper</td><td align="left" valign="bottom">NEVGFRGFYPAHGTKL<break/>NVSTEALQKAVKLFSDIEN</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">BRC7- peptide</td><td align="left" valign="bottom">Pierce, This paper</td><td align="left" valign="bottom">SANTCGIFSTASGKSVQ<break/>VSDASLQNARQVFSEIED</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Peptide, <break/>recombinant <break/>protein</td><td align="left" valign="bottom">BRC7- T1980I <break/>peptide</td><td align="left" valign="bottom">Pierce, This paper</td><td align="left" valign="bottom">SANTCGIFSIASGKSVQV<break/>SDASLQNARQVFSEIED</td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-MBP (mouse monoclonal)</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">Cat# E8032L</td><td align="left" valign="bottom">IF (1:100)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BRCA2 (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab27976</td><td align="left" valign="bottom">IF (1:100)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BRCA2 Nt (rabbit polyclonal)</td><td align="left" valign="bottom">Bethyl Laboratories</td><td align="left" valign="bottom">Cat# A303-434</td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RAD51 (rabbit polyclonal)</td><td align="left" valign="bottom">Proteintech</td><td align="left" valign="bottom">Cat# 14961–1-AP, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2177083">AB_2177083</ext-link></td><td align="left" valign="bottom">IF (1:100)<break/>WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-RAD51 (mouse monoclonal)</td><td align="left" valign="bottom">Novus Biologicals</td><td align="left" valign="bottom">Cat# NB 100–148, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_350083">AB_350083</ext-link></td><td align="left" valign="bottom">WB (1:1000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Rabbit Anti-RAD51 (rabbit polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab63801, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_1142428">AB_1142428</ext-link></td><td align="left" valign="bottom">IF (1:100)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BrdU (purified mouse monoclonal)</td><td align="left" valign="bottom">BD Biosciences</td><td align="left" valign="bottom">Cat# 347580, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_10015219">AB_10015219</ext-link></td><td align="char" char="." valign="bottom">1:10</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-BrdU (rat monoclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6326, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2313786">AB_2313786</ext-link></td><td align="char" char="." valign="bottom">1:40</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Rat Cy5 (goat polyclonal)</td><td align="left" valign="bottom">Abcam</td><td align="left" valign="bottom">Cat# ab6565, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_955063">AB_955063</ext-link></td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">Anti-Mouse Cy3 (sheep polyclonal)</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">Cat# C2181, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:CVCL_K942">CVCL_K942</ext-link></td><td align="char" char="." valign="bottom">1:100</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">m-IgGκ BP-HRP</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-516102, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2687626">AB_2687626</ext-link></td><td align="left" valign="bottom">WB (1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-rabbit IgG-HRP (goat polyclonal)</td><td align="left" valign="bottom">Santa Cruz Biotechnology</td><td align="left" valign="bottom">Cat# sc-2004, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_631746">AB_631746</ext-link></td><td align="left" valign="bottom">WB (1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Rabbit IgG (H+L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 488 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A-11034, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2576217">AB_2576217</ext-link></td><td align="left" valign="bottom">IF (1:10000)</td></tr><tr><td align="left" valign="bottom">Antibody</td><td align="left" valign="bottom">anti-Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 546 (goat polyclonal)</td><td align="left" valign="bottom">Thermo Fisher Scientific</td><td align="left" valign="bottom">Cat# A-11003, RRID:<ext-link ext-link-type="uri" xlink:href="https://identifiers.org/RRID/RRID:AB_2534071">AB_2534071</ext-link></td><td align="left" valign="bottom">IF (1:10000)</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">dT40</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib13">Carreira and Kowalczykowski, 2011</xref></td><td align="left" valign="bottom">EMSA</td><td align="left" valign="bottom">5’TTTTTTTTTTTTTTTTTTTTTT<break/>TTTTTTTTTTTTTTTTTT3’</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">RJ-167-mer</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom">EMSA<break/>DNA strand exchange</td><td align="left" valign="bottom">5′-CTG CTT TAT CAA GAT AAT <break/>TTT TCG ACT CAT CAG AAA <break/>TAT CCG TTT CCT ATA TTT <break/>ATT CCT ATT ATG TTT TAT <break/>TCA TTT ACT TAT TCT TTA <break/>TGT TCA TTT TTT ATA TCC <break/>TTT ACT TTA TTT TCT CTG <break/>TTT ATT CAT TTA CTT ATT <break/>TTG TAT TA TCC TTA <break/>TCT TAT TTA-3′</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">RJ-5’tail 167-mer</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom">EMSA</td><td align="left" valign="bottom">: 5’-ATT TAT TCT ATT CCT CTT <break/>TAT TTT CTC TGT TTA TTC ATT <break/>TAC TTA TTT TGT ATT AAT TTC <break/>CTA TAT TTT TTA CTT GTA TTT <break/>CTT ATT CAT TTA CTT ATT TTG <break/>TAT TAT CCT TAT TTA TAT CCT <break/>TTC TGC TTT ATC AAG ATA ATT <break/>TTT CGA CTC ATC AGA <break/>AAT ATC CG-3’</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">RJ-PhiX-42–1</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom">EMSA<break/>DNA Strand Exchange</td><td align="left" valign="bottom">5’-CGG ATA TTT CTG ATG AGT <break/>CGA AAA ATT ATC TTG <break/>ATA AAG CAG-3'</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">PS4</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom">EMSA<break/>DNA Strand Exchange</td><td align="left" valign="bottom">5’- TAATACAAAATAAGTAAATGA<break/>ATAAACAGAGAAAATAAAG –3'</td></tr><tr><td align="left" valign="bottom">Sequenced-<break/>based reagent</td><td align="left" valign="bottom">PS5</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib31">Jensen et al., 2010</xref></td><td align="left" valign="bottom">EMSA<break/>DNA Strand Exchange</td><td align="left" valign="bottom">5’- CTTTATTTTCTCTGTTTATTCATT<break/>TACTTATTTTGTATTA –3'</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Jet Optimus</td><td align="left" valign="bottom">Polyplus Transfection</td><td align="char" char="ndash" valign="bottom">117–07</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Calcium Phosphate transfection</td><td align="left" valign="bottom">This paper</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.nature.com/articles/nmeth0405-319">https://www.nature.com/articles/nmeth0405-319</ext-link></td><td align="left" valign="bottom">Dr. Ryan Jensen laboratory. <break/>Material &amp; Methods section</td></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Lipofectamine3000</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">L3000001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">TurboFect reagent</td><td align="left" valign="bottom">Thermo Scientific</td><td align="left" valign="bottom">R0533</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">G418</td><td align="left" valign="bottom">American Bio</td><td align="left" valign="bottom">AB05058-00020</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">protease inhibitor cocktail</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="char" char="." valign="bottom">04693159001</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">amylose resin</td><td align="left" valign="bottom">NEB</td><td align="left" valign="bottom">E8021</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Hydroxyurea</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="char" char="hyphen" valign="bottom">127-07-1</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Benzonase</td><td align="left" valign="bottom">Millipore</td><td align="char" char="hyphen" valign="bottom">9025-65-4</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">MMC</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">M4287</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Cisplatin</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="char" char="hyphen" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.sigmaaldrich.com/US/en/search/15663-27-1?focus=products&amp;page=1&amp;perPage=30&amp;sort=relevance&amp;term=15663-27-1&amp;type=cas_number">15663-27-1</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Olaparib</td><td align="left" valign="bottom">ApexBio</td><td align="left" valign="bottom">AZD2281, Ku-0059436</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">Talazoparib-BMN673</td><td align="left" valign="bottom">ApexBio</td><td align="left" valign="bottom">A4153</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">DTT</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="char" char="hyphen" valign="bottom">3483-12-3</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">IdU</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">I7125</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">CldU</td><td align="left" valign="bottom">Sigma Aldrich</td><td align="left" valign="bottom">C6891</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Chemical <break/>compound, drug</td><td align="left" valign="bottom">FluorSave reagent</td><td align="left" valign="bottom">Calbiochem</td><td align="char" char="." valign="bottom">345789</td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">ClustalIX</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib38">Larkin et al., 2007</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.ch.embnet.org/software/ClustalW.html">http://www.ch.embnet.org/software/ClustalW.html</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Bioedit</td><td align="left" valign="bottom">Bioedit (<xref ref-type="bibr" rid="bib26">Hall, 1999</xref>)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://itservices.cas.unt.edu/software/bioedit725">https://itservices.cas.unt.edu/software/bioedit725</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Snapgene 5.3.1.</td><td align="left" valign="bottom">Snapgene 5.3.1.</td><td align="left" valign="bottom">from Insightful Science; <break/>available at <ext-link ext-link-type="uri" xlink:href="https://www.snapgene.com/">snapgene.com</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Prism Graph Pad version 9.0</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.graphpad.com/updates/prism-900-release-notes">https://www.graphpad.com/updates/prism-900-release-notes</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">PyMOL Molecular Graphics System, Version 1.3 <break/>Schrödinger, LLC.</td><td align="left" valign="bottom">Schrodinger, L. (2010) The <break/>PyMOL Molecular <break/>Graphics System</td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Image J</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib60">Schneider et al., 2012</xref></td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://imagej.nih.gov/ij/">https://imagej.nih.gov/ij/</ext-link></td><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">ImageQuant TL 8.0 image analysis software</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="http://www.hhmi.umbc.edu/downloads/Imaging%20support%20GE/IQ%20TL%20collateral/IQTL_UserManual%208.pdf">http://www.hhmi.umbc.edu/downloads/Imaging%20support%20GE/IQ%20TL%20collateral/IQTL_UserManual%208.pdf</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Image Lab Software 6.1 (Bio-Rad)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.bio-rad.com/en-us/product/image-lab-software?ID=KRE6P5E8Z&amp;WT.mc_id=220411034041&amp;WT.knsh_id=_kenshoo_clickid_&amp;gclid=Cj0KCQjwr4eYBhDrARIsANPywCiJded2fEKfZWaf_-Fxki9ynO1VFgLb3kkN-gJ-A3u4baPwfvKj2ZQaApk-EALw_wcB">https://www.bio-rad.com/en-us/product/image-lab-software?ID=KRE6P5E8Z&amp;WT.mc_id=220411034041&amp;WT.knsh_id=_kenshoo_clickid_&amp;gclid=Cj0KCQjwr4eYBhDrARIsANPywCiJded2fEKfZWaf_-Fxki9ynO1VFgLb3kkN-gJ-A3u4baPwfvKj2ZQaApk-EALw_wcB</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">ChemiDoc MP imaging system XRS+ (Bio-Rad)</td><td align="left" valign="bottom"><ext-link ext-link-type="uri" xlink:href="https://www.bio-rad.com/en-us/product/chemidoc-mp-imaging-system?ID=NINJ8ZE8Z&amp;gclid=Cj0KCQjwr4eYBhDrARIsANPywCjmMNj5mMKTHZkXXj4iOrhnRLMo8JRt4nwLib3XTupvbHi2Q2CRJnkaAvp6EALw_wcB">https://www.bio-rad.com/en-us/product/chemidoc-mp-imaging-system?ID=NINJ8ZE8Z&amp;gclid=Cj0KCQjwr4eYBhDrARIsANPywCjmMNj5mMKTHZkXXj4iOrhnRLMo8JRt4nwLib3XTupvbHi2Q2CRJnkaAvp6EALw_wcB</ext-link></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Software, <break/>algorithm</td><td align="left" valign="bottom">Cell profiler software following counting and scoring pipeline</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib11">Carpenter et al., 2006</xref></td><td align="left" valign="bottom"/><td align="left" valign="bottom"/></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">PDB structure BRC4</td><td align="left" valign="bottom"><xref ref-type="bibr" rid="bib53">Pellegrini et al., 2002</xref></td><td align="char" char="." valign="bottom">1NOW</td><td align="left" valign="bottom">Swiss model BRC2-7</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">DAPI stain</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">D1306</td><td align="left" valign="bottom">(1 µg/mL)</td></tr><tr><td align="left" valign="bottom">Other</td><td align="left" valign="bottom">NucRed Live 647 ReadyProbes Reagent</td><td align="left" valign="bottom">Thermo Fisher</td><td align="left" valign="bottom">R37106</td><td align="left" valign="bottom">(1 µg/mL)</td></tr></tbody></table></table-wrap></app></app-group></back><sub-article article-type="editor-report" id="sa0"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79183.sa0</article-id><title-group><article-title>Editor's evaluation</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Aguilera</surname><given-names>Andrés</given-names></name><role specific-use="editor">Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yxnpp24</institution-id><institution>CABIMER, Universidad de Sevilla</institution></institution-wrap><country>Spain</country></aff></contrib></contrib-group><related-object id="sa0ro1" object-id-type="id" object-id="10.1101/2021.09.24.461749" link-type="continued-by" xlink:href="https://sciety.org/articles/activity/10.1101/2021.09.24.461749"/></front-stub><body><p>This study provides a thorough functional analysis of three mutations in the BRCA2 gene that do not seem to necessarily cause breast cancer. The authors use functional assays in cancer cells and with recombinant proteins to determine that two BRCA2 variants, S1221P and T1980I, are indeed pathogenic, while the T13461 variant is fully functional and benign. The strength of the study is the rigorous assessment of these mutations in a variety of established assays for BRCA2, and has improved significantly following the review process. The work should have a broad impact in the breast cancer field.</p></body></sub-article><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79183.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Aguilera</surname><given-names>Andrés</given-names></name><role>Reviewing Editor</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/03yxnpp24</institution-id><institution>CABIMER, Universidad de Sevilla</institution></institution-wrap><country>Spain</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Hengel</surname><given-names>Sarah R</given-names></name><role>Reviewer</role><aff><institution-wrap><institution-id institution-id-type="ror">https://ror.org/01an3r305</institution-id><institution>University of Pittsburgh School of Medicine</institution></institution-wrap><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text id="sa2-box1"><p>Our editorial process produces two outputs: (i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2021.09.24.461749">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2021.09.24.461749v2">the preprint</ext-link> for the benefit of readers; (ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;BRCA2 BRC missense variants disrupt RAD51-dependent DNA repair&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, and the evaluation has been overseen by a Reviewing Editor and Päivi Ojala as the Senior Editor. The following individual involved in the review of your submission has agreed to reveal their identity: Sarah R Hengel (Reviewer #2).</p><p>The reviewers have discussed their reviews with one another, and the Reviewing Editor has drafted this to help you prepare a revised submission.</p><p>Essential revisions:</p><p>1) Figure 1 It would be helpful to add a control with DLD1 BRCA2-proficient cells for visualization of the endogenous BRCA2 expression level.</p><p>2) Figure S3. Quantitation of the plating efficiencies needs to be included.</p><p>3) Figure 5B shows a disproportionally stronger decrease in the free DNA bands than an increase in the RAD51-ssDNA complexes, which may indicate the presence of nucleases. Were the nucleases tested in the protein preps?</p><p>4) Figure 5E. In fact, BRC7-T1980I shows a noticeable increase in RAD51 capture.</p><p>5) Abstract: It may be helpful to tune readers into what kind of cells you are performing your analysis with: DLD-1 colorectal cancer cells – think about adding it to the abstract.</p><p>6) Page 3: When introducing DBD of BRCA2, the NLS info should be mentioned here in coordination with DSS1. As written the NLS is described only in context to the C-terminus.</p><p>7) Page 4: What is the total number of missense mutations in the whole BRCA2 protein? And how does this compare to the number of missense mutations in the BRC repeats? While the authors note that VUSs are frequently found to be unique to individual families – are there missense mutations that are more frequently populated? How did you focus on the two mutations within BRC repeats – was it first using a reductionist approach to focus in on amino acid conservation?</p><p>8) Page 15: It is unclear if the BRCA2 T1346I variant has been published before? Is there anything else known about this mutation and the tumor mutational burden? What happened to the patient? Did they survive?</p><p>9) Page 16: Explicitly state which modeling algorithms were used and how the computational structural analysis was performed in the text of the manuscript.</p><p>10) Page 16: Adjust this sentence and describe the loop either in amino acids etc… (However, polar contacts within a loop,&quot; is a bit vague and I am not certain what the authors are trying to explain.</p><p>11) Page 17: &quot;….re-introduction of recombinant BRCA2 protein in deficient cells increases total expression of RAD51&quot; Do you think this is a chromatin or protein phenomenon. It would be interesting to hear about the authors' thoughts in the discussion on this repeatable result.</p><p>12) When describing cell-based assays throughout the manuscript text please explicitly list the cell type-either DLD-1 or HEK293 cells within the manuscript where the assays are described (Example-page 18 affects HDR (Figure 3A).</p><p>13) Page 19: Title: Individual S1221P and T1980I BRC mutations eliminate binding to RAD51 I suggest adding DLD-1 cells at the end of the title. Would the same conclusions be drawn if the assays were performed in other cell lines? It may be useful to be more specific in language.</p><p>14) Page 20: It has been shown in our field using single-molecule FRET assays that measure RAD51 nucleation, that RAD51 nucleates as dimers and multimers of dimers etc via transition density hidden Markov analysis (Subramanyam et al., 2018 (PMID: 29458759)). This paper should be cited in the sentence that begins with &quot;To reconcile our pulldown-data…..&quot;</p><p>15) Page 22: Could it be possible that BRC7 may be changing the conformation of RAD51 to adopt a more ATP-bound or open conformation responsible for the lower FRET state (0.7)? FRET values do not allow the authors to conclude that RAD51 nucleation is stimulated. These data simply show a change in the conformation of the DNA substrate. I would suggest re-wording this section. It is also plausible that BRC2WT would show a lower FRET value at higher protein concentrations than those assayed (20 nM BRC2WT + 20 nM RAD51). Did the authors try increasing the protein concentrations in this assay?</p><p>16) Page 22: What is the photobleaching lifetime in the FRET experiments? This should be included for publication as well as the buffer components and any photostabilizers utilized. The imaging time etc should also be reported. Were there any lifetime differences between the various mutants?</p><p>17) It is conceivable that the impact of the study could be improved with the presentation of the data, particularly in the Discussion. Namely – what new information do we have about the BRC repeat function from this study? Alternatively, perhaps the authors could explain why they chose to test 3 alleles in the BRC repeat region in lots of assays, instead of large-scale testing of VUSs in the BRC repeat region in a couple of assays?</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.79183.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>1) Figure 1 It would be helpful to add a control with DLD1 BRCA2-proficient cells for visualization of the endogenous BRCA2 expression level.</p></disp-quote><p>We believe the reviewer is referring to the western blot in Figure 2A. We have performed the requested experiment which is included in the manuscript as Figure 2-supplement figure 1 revised. As well, we have included the corresponding changes in the figure legend and manuscript file.</p><disp-quote content-type="editor-comment"><p>2) Figure S3. Quantitation of the plating efficiencies needs to be included.</p></disp-quote><p>We believe the reviewer is referring to Figure 2-supplement figure 2. We have quantitated the plating efficiencies as requested now included as figure2-supplement figure 2B and figure2-supplement figure 2-source data 1-revised plating efficiency.</p><disp-quote content-type="editor-comment"><p>3) Figure 5B shows a disproportionally stronger decrease in the free DNA bands than an increase in the RAD51-ssDNA complexes, which may indicate the presence of nucleases. Were the nucleases tested in the protein preps?</p></disp-quote><p>Yes, all purified proteins were found to be free of contaminating nucleases. Please see included file depicting nuclease assays performed on purified proteins.</p><disp-quote content-type="editor-comment"><p>4) Figure 5E. In fact, BRC7-T1980I shows a noticeable increase in RAD51 capture.</p></disp-quote><p>We do note that BRC7-T1980I shows a 2.5-fold reduction in RAD51 capture compared to WT BRC7 and yet exhibits higher levels of RAD51 bound than the RAD51 alone (lane 3). Perhaps there is a residual binding mode specific to the RAD51 filament that is retained by the BRC7-T1980I mutant, however, extensive further characterization of BRC-RAD51 binding modes will be required to understand the specific interactions which is beyond the scope of this manuscript. We now include discussion of this result in the manuscript (page 24).</p><p>“Interestingly, residual RAD51-ssDNA binding was observed with BRC7-T1980I (compare lane 15 to lane 3 in Figure 5E) perhaps indicative of a binding mode specific to BRC7 that is not completely diminished by the T1980I mutation.”</p><disp-quote content-type="editor-comment"><p>5) Abstract: It may be helpful to tune readers into what kind of cells you are performing your analysis with: DLD-1 colorectal cancer cells – think about adding it to the abstract.</p></disp-quote><p>We appreciate the reviewer’s suggestion; however, we have done extensive analysis in both DLD1 and HEK293T cells. To help guide readers, we now explicitly state which cell line was used in each experiment throughout the manuscript.</p><disp-quote content-type="editor-comment"><p>6) Page 3: When introducing DBD of BRCA2, the NLS info should be mentioned here in coordination with DSS1. As written the NLS is described only in context to the C-terminus.</p></disp-quote><p>To clarify this point, we have added some text on pages 3 and 4:</p><p>“A nuclear export sequence (NES) in the DBD has been found to overlap with the binding region for DSS1 and a specific missense mutation (D2723H) that disrupts DSS1 binding results in BRCA2 export to the cytoplasm (Jeyasekharan et al., 2013).”</p><p>“Putative nuclear localization signals (NLSs) are located in the CTD of BRCA2, however, surprisingly, it remains unclear how exactly nuclear/cytoplasmic trafficking of BRCA2 is regulated (Bertwistle et al., 1997; Han et al., 2008; Spain et al., 1999; Yano et al., 2000) (reviewed in Jimenez-Sainz and Jensen, 2021).</p><p>“We and others have recently discovered that missense mutations in the DBD mislocalized BRCA2 to the cytosol leading to HR deficiency and sensitivity to crosslinking agents and PARPi (Jeyasekharan et al., 2013; Lee et al. 2021; Jimenez-Sainz and Jensen, 2021; Jimenez-Sainz, 2022).”</p><disp-quote content-type="editor-comment"><p>7) Page 4: What is the total number of missense mutations in the whole BRCA2 protein? And how does this compare to the number of missense mutations in the BRC repeats? While the authors note that VUSs are frequently found to be unique to individual families – are there missense mutations that are more frequently populated? How did you focus on the two mutations within BRC repeats – was it first using a reductionist approach to focus in on amino acid conservation?</p></disp-quote><p>The total number of BRCA2 variants in Clin Var (accessed 2022-07-12) is 15,079 of which 6,541 are missense. The total number of BRC variants is 4,234 of which 2,114 are missense. Thus, almost 50% of the BRC variants are missense and 32% of missense variants are located in the BRC domain. Most missense variants in the BRC domain are of uncertain significance (97%) therefore it is unknown how mutations in this essential domain could affect cancer risk.</p><p>Clinically, most germline truncating pathogenic mutations in BRCA2 occur in the BRC repeat region. Because secondary reversion events that lead to in-frame deletions cluster in the BRC repeats, we feel it is important to fully characterize this region to further understand both chemotherapeutic resistance mechanisms as well as the biological role of the BRC repeats. Additionally, germline or somatic missense mutations in the BRC repeats are not well characterized and likely contribute to cancer risk and therapy response.</p><p>In the breast cancer information core database (BIC), there are three common missense mutations in the BRC repeats: D1420Y (Submissions 200, Exact 0.0068, https://www.ncbi.nlm.nih.gov/clinvar/variation/41549/), R2034C (Submissions 104, Exact 0.0032, https://www.ncbi.nlm.nih.gov/clinvar/variation/41558/?new_evidence=false) and D1902N (Submissions 87, Exact 0.0017, https://www.ncbi.nlm.nih.gov/clinvar/variation/51912/?new_evidence=false).</p><p>However, these missense mutations have been reviewed by an expert panel designated as benign.</p><p>Based on the analysis presented in this study, we predict that D1420Y, R2034C, and D1902N do not alter RAD51 binding and/or function due to their locations in the spacer regions between BRC repeats as well as lack of conservation across species. (D1420Y is in the spacer between BRC2 and BRC3, D1902N is in the spacer between BRC6 and BRC7, and R2034C is in the spacer between BRC7 and BRC8).</p><p>We initially focused on the T1980I variant as its location within the conserved FxTAS motif predicted disruption of RAD51 binding. Previously, we and others had shown that BRC repeats 1-4 behave differently than BRC repeats 5-8 (Carreira and Kowalczykowski, 2011; Chatterjee et al., 2016) and given that T1980I resides in BRC7, we decided to characterize S1221P in BRC2 to compare BRC repeats from the two modules. Again, due to the location of the S1221P mutation in the FxTAS motif, it seemed likely that this variant would disrupt RAD51 binding. The T1346I variant was brought to our attention by Paul Eder, MD, a medical oncologist at Yale, who was treating a colon cancer patient and enrolling patients into a PARP inhibitor clinical trial. The variant was identified by whole exome sequencing of the patient’s colon tumor. We found T1346I of interest as the mutation was located in the spacer region between BRC repeats and it was unclear if this variant was pathogenic or benign.</p><disp-quote content-type="editor-comment"><p>8) Page 15: It is unclear if the BRCA2 T1346I variant has been published before? Is there anything else known about this mutation and the tumor mutational burden? What happened to the patient? Did they survive?</p></disp-quote><p>This is the first report of the T1346I variant to our knowledge. Three other missense changes in the T1346 residue have been deposited in ClinVar as variants of uncertain significance (T1346A, T1346S and T1346N) (https://www.ncbi.nlm.nih.gov/clinvar/?term=brca2%5Bgene%5D+T1346).</p><p>The patient did not have any known family history of cancer and did not respond to standard of care chemotherapy (FOLFOXIRI) [ 5 – Fluorouracil/leucovorin/oxaliplatin/irinotecan]. The patient declined to enroll in clinical trial NCT02576444 (olaparib combinations), elected hospice care, and died soon thereafter.</p><disp-quote content-type="editor-comment"><p>9) Page 16: Explicitly state which modeling algorithms were used and how the computational structural analysis was performed in the text of the manuscript.</p></disp-quote><p>The requested information is now included on page 6 (Material and Methods section) and on page 17 (Results section).</p><p>“SWISS-Model website: &quot;Models are computed by the SWISS-MODEL server homology modelling pipeline (Waterhouse et al.) which relies on ProMod3 (Studer et al.), an in-house comparative modelling engine based on OpenStructure (Biasini et al.).”</p><disp-quote content-type="editor-comment"><p>10) Page 16: Adjust this sentence and describe the loop either in amino acids etc… (However, polar contacts within a loop,&quot; is a bit vague and I am not certain what the authors are trying to explain.</p></disp-quote><p>The sentence has been changed to clarify:</p><p>“Modeling of the T1526A substitution does not lead to steric clashing, however, could disassemble the BRC4 loop conformation (hydrophobic contacts F1524, A1527 and K1530 and polar contacts T1526 and S1528) necessary for RAD51 binding (Figure 1—figure supplement 1) (Carreira <italic>et al.</italic>, 2009). ”</p><disp-quote content-type="editor-comment"><p>11) Page 17: &quot;….re-introduction of recombinant BRCA2 protein in deficient cells increases total expression of RAD51&quot; Do you think this is a chromatin or protein phenomenon. It would be interesting to hear about the authors' thoughts in the discussion on this repeatable result.</p></disp-quote><p>We think BRCA2 and RAD51 protein levels are mutually dependent as described in this publication (https://pubmed.ncbi.nlm.nih.gov/24210700/) and we speculate that BRCA2 and RAD51 positively regulate the stability of each other. In supplementary figure 6 of our previous publication (Chatterjee et al. 2016, NAR) re-introduction of BRC1-8 or full-length BRCA2 increased the total expression of RAD51 in cellular assays and this observation was discussed in detail in the Discussion section of the prior publication. Further analysis will be required to define the molecular regulation of protein stability between the BRCA2 and RAD51 proteins.</p><disp-quote content-type="editor-comment"><p>12) When describing cell-based assays throughout the manuscript text please explicitly list the cell type-either DLD-1 or HEK293 cells within the manuscript where the assays are described (Example-page 18 affects HDR (Figure 3A).</p></disp-quote><p>As requested, the manuscript was revised to specify whether DLD1 or 293T cells were utilized on pages 19, 20 and 21</p><disp-quote content-type="editor-comment"><p>13) Page 19: Title: Individual S1221P and T1980I BRC mutations eliminate binding to RAD51 I suggest adding DLD-1 cells at the end of the title. Would the same conclusions be drawn if the assays were performed in other cell lines? It may be useful to be more specific in language.</p></disp-quote><p>Indeed, experiments were performed in DLD-1 and 293T cells as well as using purified proteins all coming to the same conclusion. The manuscript was updated to specify which cell lines were used or whether purified proteins were used.</p><disp-quote content-type="editor-comment"><p>14) Page 20: It has been shown in our field using single-molecule FRET assays that measure RAD51 nucleation, that RAD51 nucleates as dimers and multimers of dimers etc via transition density hidden Markov analysis (Subramanyam et al., 2018 (PMID: 29458759)). This paper should be cited in the sentence that begins with &quot;To reconcile our pulldown-data…..&quot;</p></disp-quote><p>We thank the reviewer for bringing this to our attention. We have now added the citation.</p><disp-quote content-type="editor-comment"><p>15) Page 22: Could it be possible that BRC7 may be changing the conformation of RAD51 to adopt a more ATP-bound or open conformation responsible for the lower FRET state (0.7)? FRET values do not allow the authors to conclude that RAD51 nucleation is stimulated. These data simply show a change in the conformation of the DNA substrate. I would suggest re-wording this section. It is also plausible that BRC2WT would show a lower FRET value at higher protein concentrations than those assayed (20 nM BRC2WT + 20 nM RAD51). Did the authors try increasing the protein concentrations in this assay?</p></disp-quote><p>While we acknowledge that smFRET can not directly measure RAD51 nucleation/filament formation, given the extensive literature on the ability of RAD51 to nucleate, form filaments, and stretch DNA, we argue that this is the behavior we are observing. Nonetheless, we appreciate the reviewer’s comment regarding the idea that BRC repeats may induce conformational changes in RAD51 translating into conformational changes in the DNA substrate and will include this possible interpretation in the Discussion section of the manuscript.</p><p>An interesting point concerns the way BRC2 and BRC7 may bind RAD51 differently. If BRC2 and BRC7 had equivalent binding modalities to RAD51, one would expect that both BRCs (2 and 7) would contribute to a similar extent in RAD51 conformational dynamics. But we do not see that in our experiments. As the reviewer rightfully pointed out, our measurements only show changes in DNA dynamics, therefore, we concluded that since RAD51 and BRC7 individually (at 20 nM) did not show any change in DNA conformation, but together they did, and given that BRC7 has a preference for RAD51 filaments, it is possible that BRC7 is stimulating RAD51 nucleation and/or filament formation in a different manner than BRC2.</p><p>As mentioned in the results, we performed experiments with BRC2 and BRC7 in the concentration range of 50-100 nM. We note that even at higher concentrations of BRC7, we observed the same magnitude of FRET change with 20 nM RAD51 and observed no change with BRC2. We could not perform the experiments with higher concentrations of RAD51, as even with 40-50 nM RAD51, we see low FRET populations consistent with what was reported previously by Maria Spies and co-workers (Subramanyam et al., 2018 (PMID: 29458759)). Under our conditions, 20 nM RAD51 was the highest concentration obtainable that did not result in a change in FRET but allowed us to measure stimulation by BRC7.</p><disp-quote content-type="editor-comment"><p>16) Page 22: What is the photobleaching lifetime in the FRET experiments? This should be included for publication as well as the buffer components and any photostabilizers utilized. The imaging time etc should also be reported. Were there any lifetime differences between the various mutants?</p></disp-quote><p>We apologize for the lack of clarity but photobleached samples were not included in our analysis. Moreover, we are using a method that was previously published (citation number 35 (page 32)):</p><p>“Marsden, C.G., Jensen, R.B., Zagelbaum, J., Rothenberg, E., Morrical, S.W., Wallace, S.S., and Sweasy, J.B. (2016). The Tumor-Associated Variant RAD51 G151D Induces a Hyper-Recombination Phenotype. PLoS Genet <italic>12</italic>, e1006208. 10.1371/journal.pgen.1006208.”.</p><p>However, as per reviewer’s suggestion, we have updated the methods and provided additional details.</p><p>Single molecule Förster Resonance Energy Transfer (smFRET)</p><p>“All reactions were performed at room temperatures in imaging buffer consisting of 50 mM Tris-HCl, pH 8.0, 1 mM MgCl2, 2 mM CaCl<sub>2</sub>, 2 mM ATP, 0.1 mg/ml BSA, 25% glucose, Trolox and 1% Gloxy (80% of imaging buffer, 20% catalase and 10 mg glucose oxidase) as described in Marsden et al. (Marsden et al., 2016). 20 nM BRC peptides were pre-incubated with 20 nM RAD51 in a 1:1 ratio for 15 minutes at 37 <sup>o</sup>C followed by the addition of the protein complexes to 300 pM DNA that was tethered to a PEG-coated quartz surface through biotin-neutravidin linkage. smFRET assays were performed as described in (Marsden et al., 2016; Rothenberg and Ha, 2010). Briefly, a custom-built optical imaging platform in reference to Olympus IX70 inverted microscope was used, which was coupled to a 532 (10 mWatts) and a 640 (10 mWatts) nm solid -state lasers to excite the sample in the TIRF mode. Photons collected from the Cy3 and Cy5 fluorophores were then imaged on to a single EMCCD camera (Andor iXon3) with images acquired at 33 Hz and EM gain set to 300. Data consisting of 500 frames were recorded with each frame having an exposure time of 30 ms and analyzed as indicated in Marsden et al. Matlab (version R2020b) was used to view and analyze the FRET trajectories. The FRET histograms were generated using a sample size of at least 250 single molecule trajectories and the representative histograms did not include zero FRET values or photobleached portions of the FRET trajectories. Origin (version 2021) was used to plot the histograms and the FRET trajectories.”</p><disp-quote content-type="editor-comment"><p>17) It is conceivable that the impact of the study could be improved with the presentation of the data, particularly in the Discussion. Namely – what new information do we have about the BRC repeat function from this study? Alternatively, perhaps the authors could explain why they chose to test 3 alleles in the BRC repeat region in lots of assays, instead of large-scale testing of VUSs in the BRC repeat region in a couple of assays?</p></disp-quote><p>The goal of this study was two-fold: (1) to identify novel pathogenic variants within the BRC repeats of BRCA2 with implications for cancer risk in patients, and (2) to leverage deleterious BRC variants to elucidate the specific functions of each BRC repeat within the context of the full-length BRCA2 protein. Our study revealed several novel insights including: (1) the findings that individual BRC repeat mutations impair the HDR functions within the context of the full-length BRCA2 protein in both cellular and biochemical assays despite the presence of the remaining functional BRC repeats, (2) BRC7 alone can bind RAD51, (3) a tumor-derived variant located within a spacer region between BRC repeats did not alter BRCA2 function, (4) BRC7 appears to stimulate RAD51 nucleation/filament stability in a different manner than BRC2, and (5) utilizing the RAD51 T131P mutation (incapable of self-association and filament formation), we confirmed binding to BRC2 but not BRC7, providing additional evidence that BRC repeats 1-4 engage monomeric RAD51 whereas BRC repeats 5-8 interact with the filament form of RAD51.</p><p>An important point regarding large-scale studies of BRCA2 VUS is that the specific functions of BRCA2 required for tumor suppression have not been rigorously identified. Our assumption that homology-directed repair (RAD51 loading and stimulation of RAD51 nucleation) is the key mechanism seems likely but still needs to be proven. BRCA2 is a large, complex protein with both caretaker and tumor suppressor functions that are paradoxically required for viability, and yet, loss of BRCA2 function in somatic cells drives tumor initiation and/or progression. In-depth analysis of the underlying biological role of specific BRCA2 domains, including the modular BRC repeats, will help elucidate the features required for both cell viability and tumor suppressor functions. For large-scale testing of BRCA2 VUS to be successful to predict cancer risk, we need to carefully consider the specific functions analyzed in the assay (rescue of viability? canonical HDR functions? fork protection?). To date, there is no assay that directly measures the tumorigenic capacity of BRCA2 mutations as has been done for certain oncogenes. With this in mind, we should proceed with caution in terms of clinical integration of functional assays into genetic counseling until we fully understand how specific variants will impact the tumor suppressor functions of BRCA2.</p></body></sub-article></article>